



(86) Date de dépôt PCT/PCT Filing Date: 2011/08/08
(87) Date publication PCT/PCT Publication Date: 2012/04/05
(45) Date de délivrance/Issue Date: 2019/06/18
(85) Entrée phase nationale/National Entry: 2013/02/07
(86) N° demande PCT/PCT Application No.: IB 2011/053535
(87) N° publication PCT/PCT Publication No.: 2012/042404
(30) Priorité/Priority: 2010/08/09 (US61/371,984)

(51) Cl.Int./Int.Cl. *C07C 69/16* (2006.01),
A01N 65/24 (2009.01), *A01P 1/00* (2006.01),
A23L 3/3472 (2006.01), *A23L 3/3517* (2006.01),
A61K 31/22 (2006.01), *A61K 36/54* (2006.01),
A61P 31/00 (2006.01)
(72) Inventeurs/Inventors:
HERNANDEZ-BRENES, CARMEN, MX;
GARCIA-CRUZ, MARIA ISABEL, MX;
GUTIERREZ-URIBE, JANET ALEJANDRA, MX;
BENAVIDES-LOZANO, JORGE ALEJANDRO, MX;
RODRIGUEZ-SANCHEZ, DARIANA GRACIELA, MX
(73) Propriétaires/Owners:
AVOMEX, INC., US;

(54) Titre : ACTIVITE D'INHIBITION DE GERMINATION DE SPORE ANTIMICROBIENNE ET ANTIBACTERIENNE A PARTIR D'ACETOGENINES DE L'AVOCAT
(54) Title: ANTIMICROBIAL, ANTIBACTERIAL AND SPORE GERMINATION INHIBITING ACTIVITY FROM AVOCADO ACETOGENINS

(57) **Abrégé/Abstract:**

The present invention relates to extracts from *Persea* sp. (avocado) enriched in bioactive compounds which can be used as antimicrobial, antibacterial or spore germination inhibiting agents, the process for obtaining the extracts, acetogenins and isolated molecules and methods for using the extracts enriched in bioactive compounds for providing antimicrobial, antibacterial or spore germination inhibiting effect.

(73) **Propriétaires(suite)/Owners(continued):**

INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY, MX

(74) **Agent:** GOWLING WLG (CANADA) LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2012/042404 A3

(43) International Publication Date
5 April 2012 (05.04.2012)

(51) International Patent Classification:
A61K 8/97 (2006.01)

(21) International Application Number:
PCT/IB2011/053535

(22) International Filing Date:
8 August 2011 (08.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/371,984 9 August 2010 (09.08.2010) US

(71) Applicants (for all designated States except US): **INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY** [—/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey, C.P. 64849 (MX). **AVOMEX, INC.** [US/US]; 3000 Galvez Ave., Fort Worth, TX 76111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HERNANDEZ-BRENES, Carmen** [CR/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey, C.P. 64849 (MX). **GARCIA-CRUZ, Maria Isabel** [MX/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey, C.P. 64849 (MX). **GUTIERREZ-URIBE, Janet Alejandra** [MX/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey, C.P. 64849 (MX). **BENAVIDES-LOZANO, Jorge Alejandro** [MX/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey,

C.P. 64849 (MX). **RODRIGUEZ-SÁNCHEZ, Dariana Graciela** [MX/MX]; Ave. Eugenio Garza Sada Sur 2501, Col. Tecnológico, Nuevo Leon, Monterrey, C.P. 64849 (MX).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:
1 November 2012

(54) Title: ANTIMICROBIAL, ANTIBACTERIAL AND SPORE GERMINATION INHIBITING ACTIVITY FROM AN AVO-CADO EXTRACT ENRICHED IN BIOACTIVE COMPOUNDS

(57) Abstract: The present invention relates to extracts from Persea sp. (avocado) enriched in bioactive compounds which can be used as antimicrobial, antibacterial or spore germination inhibiting agents, the process for obtaining the extracts, acetogenins and isolated molecules and methods for using the extracts enriched in bioactive compounds for providing antimicrobial, antibacterial or spore germination inhibiting effect.



WO 2012/042404 A3

Title: Antimicrobial, antibacterial and spore germination inhibiting activity from avocado acetogenins

BACKGROUND OF THE INVENTION

1. Technical Field

Some technical definitions relevant to the invention include “non-spore forming bacteria” which is a known term used for pathogenic and spoilage bacteria that cannot form bacterial spores and can be destroyed or controlled by a heat treatment, refrigerated anaerobic storage, antibacterial substances and other methods known in the art used alone or in combination. Another relevant term is “spore forming bacteria”, which includes pathogenic and spoilage bacterial capable of forming very resistant structures called bacterial spores (also termed endospores) that are not necessarily destroyed or controlled by the common methods known in the art for the control of non-spore forming bacteria and require specific treatments for their inhibition and/or inactivation. Additionally, both types of bacteria can exist in nature in a “vegetative state” also termed viable cells; however spore-forming bacteria can also exist in a “spore-state” which is more resistant to chemical and physical treatments for their inactivation. In the field of food technologies there are additional bacterial states for spore forming bacteria that are artificially created by the application of heat termed “heat-shocked spores” and/or pressure “pressure-shocked spores”. The artificial states generated in the food industry result in an even higher resistance of the spores to their inactivation by chemical and physical means and in some food systems need to be controlled in order to inhibit their germination into the vegetative form of the spore forming bacteria and subsequent spoilage of the food and/or toxin production.

This invention relates to the food and pharmaceutical arts. In particular it relates to a method of inhibiting vegetative cells, spore germination and growth of gram positive bacteria by the use of chemical compounds naturally present in *Persea americana*.

The invention also relates to the medical arts. In particular it relates to a method of inhibiting the growth of pathogenic spore forming bacteria in the body including the gastrointestinal tract of a human or non-human vertebrate by the use of an antimicrobial extract with specificity for this type of bacteria.

It is known in the discipline of food processing that food products with pH values > 4.6 (commonly known in the food industry as low-acid foods) can experience the germination and growth of spore forming bacteria. Of particular interest for the food industry is the use of food additives capable of

inhibiting spore germination and vegetative cell growth from pathogenic spore forming microorganisms such as *Clostridium botulinum*, *Clostridium perfringens* and *Bacillus cereus*, among others. Under the proper food environments such as enclosed containers or anaerobic conditions generated within the food matrix the spores from these pathogenic microorganisms can germinate and grow to harmful numbers of bacterial cells and in some cases can produce toxins jeopardizing human health. Particularly, the proteolytic and non-proteolytic strains of *Clostridium botulinum* are a major concern for the food industry because of the potential germination of their bacterial spores in foods and the production of potent neurotoxins. Nitrites are the most commonly used food additives in the food industry to retard/inhibit the growth of spore forming pathogenic bacteria in refrigerated low-acid foods. However, there is a consumer and industrial long standing interest to reduce the utilization of synthetic food additives, particularly nitrite compounds. Other food additives that have been used for the same purposes include nisin (Rayman, 1981), recombinant peptides (Tang et al., 2008), 5-aminosalicylates (Lin and Pimentel, 2001) and ethyl lauroyl arginate (Beltran et al., 2011). Additionally, there have been prior patents and articles related to antimicrobial compounds from natural origin that act against bacterial vegetative cells. Many natural sources have been reported to contain antimicrobial compounds mainly lipophilic, although some hydrophilic compounds have also shown activity. Reports of antimicrobial compounds of this nature are available in literature.

The invention also relates to an important public health concern that is the ability of pathogenic species, especially the gram positive *Listeria monocytogenes*, to grow at commercial refrigeration temperatures at which processed foods are normally stored before final consumption. *Listeria monocytogenes* is a non-spore forming pathogenic bacteria of special concern for ready-to-eat meats and dairy products; as such foods are frequently not heated by the user prior to consumption. Consumption of foods contaminated with *Listeria monocytogenes* are known in the art to increase the risk of infection, especially among infants, the elderly, pregnant women, and any immune compromised individuals.

For the purposes of this invention a sporocidal agent is a substance with the ability to kill at least some types of bacterial spores whereas a sporostatic agent is a substance that has the ability to inhibit the growth and reproduction of at least some types of bacterial spores. Spore germination inhibitors include both sporocidal and sporostatic agents.

In addition, except for where otherwise indicated, depictions of the compounds described below are intended to encompass all stereoisomeric forms thereof which includes (R) and (S) forms and cis (Z) and trans (E) forms of the compounds. For the purposes of this invention, the trans (E) form can include a terminal alkene which has the formula $-\text{CH}=\text{CH}_2$ (see e.g. (2R, 16E)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-16,18-diene below).

2. Description of the Related Art

Jensen in 1951 (U.S. Patent 2,550,254) obtained an acetone extract from avocado (*Persea gratissima*) seed having antibacterial activity against vegetative cells from *Staphylococcus aureus*, *Bacillus subtilis*, *Aspergillus glaucus*, *Penicillium notatum*, and *Achromobacter perolens*. This extract was found to be inactive against *Escherichia coli*, *Pseudomonas fluorescens* and *Penicillium camemberti*. The same author in

1953 (Canada Patent 494,110) refers to avocado (*Persea americana*) seed as another natural source that might be used to obtain an extract with antimicrobial activity. Valeri and Gimeno (1954) extracted avocado seeds with petroleum ether and reported that the resulting crude wax inhibited growth of *Micrococcus pyogenes* and *Sarcina lutea*, but not growth of *B. subtilis* or of *E. coli*. The prior art indicates that avocado seeds contain antimicrobial compounds but the specific bioactivity of the extract against particular microorganisms clearly depends on the method of extraction, which in the end impacts the chemical composition of the extract.

In the related art, some compounds have been isolated from avocado seed extracts and tested to inhibit the growth of certain microorganisms (bacteria, yeasts and fungi). Kashman et al. (1969) isolated and elucidated the structure of eight compounds from a hexane extract of avocado fruit and seeds and a number of derivatives thereof were prepared, obtaining higher yields from the seeds than the fruit. All compounds showed by Kashman (1969) belong to the same group of long chain aliphatic compounds, with one end being unsaturated and the other end highly oxygenated. Interestingly the compounds were divided by the authors in pairs differing only by having a double or triple bond at the end of the chain. The isolation of these compounds was with the aim of performing a chemical characterization and not for obtaining bioactive components (not bioactivity-guided isolation). Additional studies were then performed to evaluate their antimicrobial activity against *Bacillus subtilis*, *Bacillus cereus*, *Salmonella typhi*, *Shigella dysenteriae*, *Staphylococcus aureus*, *Candida albicans*, *Saccharomyces cerevisiae* (ATCC 7752 and S 288C) (Néeman et al. 1970). Only six of twelve long-chain aliphatic compounds tested demonstrated inhibitory effects against some of the microorganisms but only 1, 2, 4-trihydroxy-n-heptadeca-16-en was capable of inhibiting the growth of all the microorganisms included in their study in a disc inhibition antimicrobial test that used 0.05 mg of the compound. The authors concluded that when the hydroxyl groups on the oxidized part of the compound were totally, or partially, acetylated, the antibacterial activity was greatly weakened (Néeman et al. 1970). Therefore acetogenins, which are the acetylated form of the above mentioned long chain aliphatic compounds, did not inhibit the growth of the previously mentioned microorganisms. Baratta et al. (1998) more recently conducted a study to evaluate the antimicrobial and antioxidant properties of an extract of essential oils from plants including laurel (*Laurus nobilis*) from the Lauraceae family but did not include the genus *Persea*.

Recently, Ugbogu and Akukwe (2009) reported on the antimicrobial effects of seed oils from *Persea gratissima* Gaertn F, among other plant seed oils, against clinical isolates of non-spore forming bacteria that included *Escherichia coli*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Staphylococcus epidermis*. The authors reported potential use of *Persea* seed oils in the treatment of wounds. Chia and Dykes (2010) also prepared ethanolic extracts from the epicarp and seed of *Persea Americana* Mill. vars. Hass, Shepard and Fuerte. They reported that at concentrations between 104.2-416.7 µg/ml, the extract showed antimicrobial activities against the growth of vegetative cells of both gram positive and gram negative bacteria; the authors also prepared a water extract that only inhibited the growth of *Listeria monocytogenes* (93.8-375 µg/ml) and *Staphylococcus epidermis* (354.2 µg/ml). Activity against *Clostridium* or *Bacillus* genus was not evaluated for the ethanolic or aqueous extract. Rodríguez-Carpena et al. (2011), in an attempt to isolate molecules with antibacterial activities, prepared extracts from the peel, pulp, and seed of two avocado cultivars (*Persea Americana* Mill.) using three

different solvents that included ethyl acetate, acetone (70%) and methanol (70%). The authors tested the antibacterial properties of the extracts against a panel of vegetative cells from non-spore forming and spore forming bacteria, concluding that their antibacterial activity was moderate and it was attributed to the presence of phenolic compounds in their extracts. Therefore the prior cited studies did not successfully performed the isolation or chemical identification of the components potentially responsible for the observed bioactivities or tested bacterial spores, heat-shocked spores or pressure-shocked spores.

Similarly, other authors have tested the antimicrobial properties of the avocado plant, against microorganisms other than bacteria. Prusky et al. (1982) described the presence of 1-acetoxy-2-hydroxy-4-oxo-heneicosa-12,15-diene (Persin) in the peel of unripe avocado fruits and attributed to the molecule the antimicrobial activity against *Colletotrichum gloeosporioides*, a fungus that causes anthracnose, a known problem encountered during storage of avocado fruits. The compound was isolated by Thin Layer Chromatography from an ethanolic extract partitioned with dichloromethane. This compound was later termed "persin" (Oelrichs et al., 1995), and was confirmed by other authors as the constituent of avocado with the highest inhibitory activity against the vegetative growth of the fungi *Colletotrichum gloeosporioides* tested *in vitro* (Sivanathan and Adikaram, 1989; Domergue et al., 2000), and with the capability to inhibit its fungi spore germination and germ tube elongation (Prusky et al., 1991a). Persin inhibited fungi spore germination completely at 790 µg/ml and the concentration of this compound in the peels was greatly reduced during ripening (Prusky et al., 1982). A monoene with similar structure, 1-acetoxy-2,4-dihydroxy-n-heptadeca-16-ene, also demonstrated bioactivity against *Colletotrichum gloeosporioides* but it was 3 fold lower than that of persin. Interestingly, a 1:1 mixture of both antifungal compounds showed synergistic activity and increased the percent of inhibited germ tube elongation of germinated conidia (Prusky et al., 1991b). Other compounds such as 1-acetoxy-2-hydroxy-4-oxo-heneicosa-5,12,15-triene (Domergue et al., 2000) have also been proven to have antifungal bioactivity. This last compound has been termed "Persenone A" (Kim et al., 2000a), however none of the isolations has been performed based on its bioactivity or with the aim of discovering novel compounds or mixtures with increased bioactivity. Most of the prior art publications have focused on finding molecules to prevent postharvest damage.

Additional bioactivities that have been reported for acetogenins included insecticidal, antitumoral, and antihelmintic properties. Persin has shown to have insecticidal activity, inhibiting the larval feeding of silkworm larvae *Bombyx mori* L., at a concentration in the artificial diet of 200 µg/g or higher (Chang et al., 1975; Murakoshi et al., 1976). More recently, Rodriguez-Saona et al. (1997) demonstrated the effects of persin on *Spodoptera exigua*, a generalist feeder insect, that does not feed on avocados, but is one of the major pests of many vegetables. Inhibitory effects were observed for both larval growth and feeding at concentrations of 200 µg/g and 400 µg/g of diet, respectively.

Persin was also identified as the active principle present in avocado leaves that induces lactating mammary gland necrosis of mice at a dose rate of 60-100 mg/kg, at doses above 100 mg/kg necrosis of mice myocardial fibers may occur, and hydrothorax may be present in severely affected animals (Oelrichs et al., 1995). Derived from this effect, this compound and others obtained from avocado leaves were patented as treatment for ovarian and breast cancer in mammals (Seawright et al., 2000). The

compounds were administered orally up to 100 mg/kg of body weight of mammal being treated, but preferably on a number of consecutive days at a concentration of 20-40 mg/kg of body weight to avoid the previously reported toxic effects. As it was previously noted, the concentration of these compounds in the avocado pulp is greatly reduced during ripening to values lower than 1500 µg/g (Kobiler et al, 1993); therefore more than 0.8 kg of avocado pulp should be consumed daily by a 60 kg human to reach the anticancer effect and even a higher concentration to reach the cytotoxic effects. The annual therapeutic dose proposed for cancer treatment is 160-fold higher than the actual annual per capita consumption of avocado in the United States (1.8 kg or 4.1 pounds) reported by Pollack et al (2010)

Persenone A, and its analog 1-acetoxy-2-hydroxy-5-nonadecen-4-one (Persenone B), along with Persin were found to inhibit superoxide (O_2^-) and nitric oxide (NO) generation in cell culture, activities that were associated by the authors to therapeutic uses as cancer chemopreventive agents in inflammation-related organs (Kim et al., 2000a, 2000b and 2000c). In vitro results demonstrated that they have equal or better activity than DHA (docosahexaenoic acid), a natural NO generation inhibitor. The IC₅₀ values were in the range of 1.2-3.5 µM for acetogenins and 4.5 µM for DHA (Kim et al., 2000a). Additionally, 1-acetoxy-2,4-dihydroxy-n-heptadeca-16-ene, persin and persenone A showed inhibition of acetyl CoA carboxylase (ACC) activity, in the IC₅₀ value range 4.0–9.4 µM (Hashimura, 2001). Authors concluded that since ACC is involved in fatty acids biosynthesis, those compounds have a potential use as fat accumulation suppressors to avoid obesity.

Most of the extraction methods for long-chain fatty acid derivatives require a previous step to recover the oil or the use of organic solvents such as hexane. The method of extraction for the identified antimicrobial compounds used by Kashman, Neeman and Lifshitz, (1969) used hexane at boiling temperatures. Broutin et al. in 2003 (U.S. Patent 6,582,688 B1) developed a method for obtaining an extract from avocado fruit oil enriched in certain class of long chain aliphatic compounds, such as furan lipid compounds and polyhydroxylated fatty alcohols. The authors claimed that different compositions of those non polar compounds may be used in different therapeutic, cosmetic and food applications. However the chemical composition of the extract obtained by their process or the content of the active molecule(s) was not specified for its use as an antimicrobial agent. Considering the toxicity of some of the compounds that might be present in a raw extract, it is extremely important to define the minimal concentration required to attain the desired effects (see U.S. Patent Application Publications 2006-0099323 and 2009-0163590).

Even if some acetogenins have been proven to have antimicrobial activity against vegetative cells of bacteria, the preliminary art does not show any reports on the bio-assay guided isolation of the antimicrobial compounds from avocado (*Persea americana*) against microorganisms, particularly sporulated forms. The present invention provides a series of steps for a process to obtain isolated compounds and/or a composition that concentrates the naturally occurring antibacterial compounds in *Persea americana* that inhibit the growth of vegetative and sporulated states of spore forming bacteria. The isolation of compounds based on inhibition of sporulated microorganisms do not form part of the teaching of the prior art. More importantly, the synergistic effect of the specific compounds in partially purified mixtures is also part of the present invention. The inventors found intriguing that the partially purified extracts and/or mixtures of isolated compounds possess spore germination inhibiting

properties, such as sporostatic and/or sporocidal properties, and in some instances even better effects than the isolated compounds alone. The chemical identity and specificity of the active compounds against spore forming microorganisms has never been previously reported nor the heat or pressure stabilities of the bioactive compounds under commercially applicable processing conditions.

Maseko (2006) proposed a simple method to produce a non acetylated fatty acid derivative called (2R, 4R)-1,2,4-trihydroxyheptadeca-16-ene by using (S)-malic acid as a cheap source of the triol fragment and the Grignard reaction to achieve the elongation of the aliphatic chain. This precursor could be used for the synthesis of most acetogenins in avocado oil. This molecule was produced as an analytical standard in Masenko (2006) and in prior art Néeman et al. (1970) had shown the potential of the compound as an antimicrobial agent against *Staphylococcus* spp., a non-spore forming bacteria. None of the cited authors tested any specific antimicrobial properties against spore forming bacteria nor a method to produce acetogenins with this particular effect.

In reference to the prior art on antimicrobial substances to be used for the specific control of vegetative cells of *Listeria monocytogenes* in refrigerated foods, U.S. Pat. No. 5,217,950 suggested the use of nisin compositions as bactericides for gram positive bacteria. U.S. Patents 5,573,797, 5,593,800 and 5,573,801 disclose antibacterial compositions which include a combination of a *Streptococcus* or *Pediococcus* derived bacteriocin or synthetic equivalent antibacterial agent in combination with a chelating agent. U.S. Pat. No. 5,458,876 suggests the combination of an antibiotic (such as nisin) with lysozyme as an antibacterial. In this case, lysozyme breaks down the cell wall and weakens the structural integrity of the target cell so that the antibacterial agent becomes more effective in damaging or killing the bacterial cell. In particular, this combination proves to be effective in improving the antibacterial -efficacy of nisin against *Listeria monocytogenes*, yielding a significant reduction, though not a complete elimination, of *Listeria* at safe and suitable levels of use. U.S. Pat. 6,620,446B2, describes an antibacterial composition for control of gram positive bacteria in food applications that may be used as an ingredient or applied to a food surface. This composition includes nisin, and/or lysozyme and beta hops acids in order to reduce or eliminate gram positive spoilage or pathogenic bacteria, and, most especially, all strains of the harmful pathogen *Listeria monocytogenes*. Perumalla and Hettiarachchy (2011) reported that green tea extract and grape seed extract (polyphenolic and proanthocyanidin rich compounds) had antimicrobial activities against major food borne pathogens like *Listeria monocytogenes*, *Salmonella typhimurium*, *Escherichia coli* O157:H7, and *Campylobacter jejuni*. Furthermore, they have demonstrated synergism in antimicrobial activity when used in combination with organic acids (malic, tartaric acid, benzoic acids etc.), bacteriocins like nisin or chelating agents like EDTA in various model systems including fresh products (fruits and vegetables), raw and ready-to-eat meat and poultry products.


Given the difficulties associated with obtaining extracts with adequate antibacterial, antimicrobial or spore germination inhibiting activities, the development of resistance by bacteria, microbes and spores to known antibacterial, antimicrobial, spore germination inhibiting compounds and compositions, and the desire for food products and medicaments of natural origin, there still exists a need in the art for additional antibacterial, antimicrobial or sporicidal compounds and compositions preferably obtained from economically feasible sources such as plant processing by-products and waste.

BRIEF SUMMARY OF THE INVENTION

This invention is directed to extracts from *Persea americana* (avocado) rich in acetogenins or its isolated molecules which can be used as antimicrobial, antibacterial or spore germination inhibiting agents. The acetogenin enriched extract presents spore germination inhibiting activity, such as sporicidal and/or sporostatic activity against native bacterial spores from *Clostridium botulinum* (proteolytic and non-proteolytic strains), *Clostridium difficile* and *Clostridium sporogenes*, and *Bacillus* spp. among other pathogenic and non-pathogenic bacteria. We also discovered that the acetogenin rich extract or its isolated molecules also presents spore germination inhibiting activity, such as sporicidal or sporostatic activity against heat-shocked and/or pressure-shocked spores of bacteria and therefore can be used in foods, cosmetics and pharmaceutical compositions to inhibit their growth. We also discovered that the enriched extract is effective as an antimicrobial agent to inhibit the growth of viable cells of other non-spore forming gram positive bacteria such as *Listeria monocytogenes*, in combination with refrigerated conditions. It is also part of this invention to protect the use of the acetogenin enriched extract in formulations that are heat treated, pressure treated or stabilized by other thermal or non-thermal conservation technologies.

In another aspect it is provided a method of inhibiting bacterial spore germination on or in a product, said method comprising:

providing an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,

A is selected from the group consisting of O and OH,


n is 0 or 1, and

m is 0 or 1;

and

applying the inhibitor compound on or in the product to inhibit bacterial spore germination on or in the product.

In a further aspect, it is provided use of an inhibitor compound of the formula



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,


A is selected from the group consisting of O and OH,

n is 0 or 1, and

m is 0 or 1;

for the inhibition of a germination of a bacterial spore in a subject.

In yet another aspect, it is provided use of an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,


A is selected from the group consisting of O and OH,

n is 0 or 1; and

m is 0 or 1;


in the manufacture of a medicament for the inhibition of germination of a bacterial spore in a subject.

In another aspect it is provided, a composition comprising an inhibitor compound of the formula:



wherein: R is selected from the group consisting of H and C₁₋₆ alkyl, A is selected from the group consisting of O and OH, n is 0 or 1, and m is 0 or 1, in a suitable carrier for use in the inhibition of a germination of a bacterial spore in a subject.

In a further aspect it is provided a compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;


A is O;

n is 0 or 1; and

m is 0 or 1.

In yet another aspect it is provided a method of providing an antimicrobial or antibacterial effect on or in a product, said method comprising:

providing an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;

A is O;


n is 0 or 1; and

m is 0 or 1.

and

applying the inhibitor compound on or in the product to provide an antimicrobial or antibacterial effect on or in the product.

In another aspect it is provided use of an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;

A is O;
n is 0 or 1; and
m is 0 or 1.

in the manufacture of a medicament for providing an antimicrobial or antibacterial effect in a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Primary extraction diagram for the compounds present in avocado seed used to evaluate their antimicrobial activities against vegetative cells, native spores and heat shocked spores of gram positive bacteria.

Figure 2. Effect of the type of extraction solvent on the antimicrobial activities of crude avocado pit extracts against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955). The extracts were tested at final concentration of 12.5 µg of solids. Data represents the average of three replications ± the standard error of the mean.

Figure 3. Effect of shaking on the extraction of antimicrobial compounds from avocado pit extracts using hexane and evaluation of their antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955). The extracts were tested at final concentration of 12.5 µg of solids. Data represents the average of three replications ± the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 4. Comparisons of the effect of extraction time using acetone or ethanol instead of hexane to obtain bioactive compounds from avocado pit that inhibit the growth of vegetative cells of *C. sporogenes* (ATCC 7955). The extracts were tested at final concentration of 12.5 µg of solids. Data represents the average of three replications ± the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 5. Comparisons of the effect of extraction time using acetone or ethanol instead of hexane to obtain bioactive compounds from avocado pit that inhibit the growth of native spores of *C. sporogenes* (ATCC 7955). The extracts were tested at final concentration of 12.5 µg of solids. Data represents the

average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 6. Comparisons of the effect of extraction time using acetone or ethanol instead of hexane to obtain bioactive compounds from avocado pit that inhibit the growth of heat-shocked spores of *C. sporogenes* (ATCC 7955). The extracts were tested at final concentration of 12.5 μg of solids. Data represents the average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 7. A) Primary extraction diagram for the compounds present in avocado seeds using acetone and their subsequent partition in a heptane:methanol system to obtain fractions F001 and F002, in each phase respectively, later used to evaluate their antimicrobial activities against vegetative cells, native spores and heat shocked spores of gram positive bacteria. **B)** Simultaneous extraction and partition diagram for the compounds present in avocado seeds using a heptane:methanol system to obtain fractions F003 and F004, respectively, later used to evaluate their antimicrobial activities against vegetative cells, native spores and heat shocked spores of gram positive bacteria.

Figure 8. Evaluation of the antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955) of extracts F001-F004 obtained as described in **Figure 7**. The extracts were tested at final concentration of 12.5 μg of solids. Data represents the average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 9. Evaluation of the antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955), of the upper and lower phases of a two phase system (ethyl acetate : water) used as a second partition of lower phase F002 (methanol) obtained as described in **Figure 7A**. The extracts were tested at final concentration of 12.5 μg of solids. Data represents the average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$). (The letter c indicates a zero cm value for the disc inhibition zone, thus no vertical bar height on the chart)

Figure 10. Evaluation of the antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955), of the upper and lower phases of a two phases system (hexane : methanol) used for partiton of the acetonic crude extract obtained as described in Example 1. The extracts were tested at final concentration of 12.5 μg of solids. Data represents the average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$).

Figure 11. Evaluation of the antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955), of the unsaponifiables compounds from the acetone raw extract obtained as described in Example 1, and the unsaponifiables compounds from the upper phase of the two phases system (hexane:methanol) used for partiton of the acetonic raw extract as described in Example 5. The extracts were tested at final concentration of 12.5 μg of solids.

Data represents the average of three replications $\pm$ the standard error of the mean. Values with the same letter are not significantly different (LSD test, $p < 0.05$). (The letter d indicates a zero cm value for the disc inhibition zone, thus no vertical bar height on chart)

Figure 12 . Evaluation of the antimicrobial activities against the growth of vegetative cells and heat shocked spores of *Clostridium sporogenes* (ATCC 7955), of the fractions obtained by reverse phase Fast Centrifugal Partition Chromatography (RP-FCPC) of the upper phase (heptane) of the two phases system (heptane:methanol) used for partition of the acetonic raw extract as described in Example 5. The solvent system used to achieve the RP-FCPC was heptane:methanol (1:1) and methanol was used as mobile phase. The fractions were tested at final concentration of 12.5 μ g of solids.

Figure 13. Evaluation of the antimicrobial activities against the growth of vegetative cells, native spores and heat shocked spores of *Clostridium sporogenes* (ATCC 7955), of the fractions obtained by Normal phase Fast Centrifugal Partition Chromatography (NP-FCPC) of the upper phase (heptane) of the two phases system (heptane:methanol) used for partition of the acetonic raw extract as described in Example 5. The solvent system used to achieve the NP-FCPC was heptane:methanol (1:1) and heptane was used as mobile phase. The fractions were tested at final concentration of 12.5 μ g of solids.

Figure 14. Evaluation of the antimicrobial activities against the growth of vegetative cells of *S. aureus* and *B. subtilis*, of the fractions obtained by Normal phase Fast Centrifugal Partition Chromatography (NP-FCPC) of the upper phase (heptane) of the two phases system (heptane:methanol) used for partition of the acetonic raw extract as described in Example 5. The solvent system used to achieve the NP-CPC was heptane:methanol (1:1) and heptane was used as mobile phase. The fractions were tested at final concentration of 12.5 μ g of solids.

Figure 15. Effect of temperature (25-100°C / 60 min) treatments of hexane and ethyl acetate upper phases obtained as described in Example 5, on the inhibitory activity of the growth of vegetative cells of *Clostridium sporogenes* (ATCC 7955).

Figure 16. Effect of temperature (25-100°C / 60 min) treatments of hexane and ethyl acetate upper phases obtained as described in Example 5, on the inhibitory activity of the growth of native spores cells of *Clostridium sporogenes* (ATCC 7955).

Figure 17. Progressive change in the chromatographic profiles of the fractions present in the active pool, obtained as described in Example 10, as their partition coefficient (K_d) increases. The fractions were analyzed by means of high performance liquid chromatography and diode array detector set at 220 nm. The numbers represent the common peaks present in different fractions.

Figure 18. Concentration of the active compounds present in the pool of active fractions described in Example 10.

DETAILED DESCRIPTION

The present invention provides a series of steps to obtain an extract that concentrates of naturally occurring antimicrobial, antibacterial or spore germination inhibiting compounds from *Persea Americana* (avocado) for providing antimicrobial, antibacterial or spore germination inhibiting effect.

In one aspect of the invention, the extract is from the seeds or the fleshy mesocarp, which is the edible portion of the avocado fruit.

In one aspect of the invention, the extraction of avocado tissues (the seeds or mesocarp) is accomplished by extraction with polar solvents and non-polar solvents.

In one embodiment of this aspect of the invention is a process of making concentrates of naturally occurring antimicrobial, antibacterial or spore germination inhibiting compounds from *Persea* sp., which includes, but is not limited to *americana* and *gratissima*, (avocado) for providing antimicrobial, antibacterial or spore germination inhibiting effect, which includes but is not limited to the growth of vegetative cells and spores of gram positive bacteria, which comprises

(a) an extraction with a polar solvent of the seeds, or other avocado plant tissues (such as the mesocarp (dried or fleshy) and/or the leaves);

(b) followed by a purification process which enriches the acetogenins from the polar solvent avocado extract or directly from the grounded seeds or other avocado plant tissues;

or

(a1) an extraction with a non-polar solvent of the seeds, or other avocado plant tissues (such as the mesocarp (dried or fleshy) and/or the leaves);

(b1) followed by a purification process which enriches the acetogenins from the non-polar solvent avocado extract or directly from the grounded seeds or other avocado plant tissues (such as the mesocarp (dried or fleshy) and/or the leaves);

In one embodiment of this aspect of the invention, the polar solvent for extraction or purification independently include (alone or mixtures), but is not limited to C₁-C₄ alcohol (e.g. methanol, ethanol, isopropanol, butanol), dimethyl sulfoxide, tetrahydrofuran, acetone, acetonitrile, or mixtures thereof.

In one embodiment of this aspect of the invention, the non polar solvent for extraction or purification independently include (alone or mixtures), but is not limited to hexanes, heptanes, ethyl ether, ethyl acetate, petroleum ether, chloroform, toluene, methyl tert-butyl ether, methyl isobutyl ketone, or mixtures thereof.

Another aspect of the invention is a purification process which enriches the acetogenins from the polar or a non-polar solvent extract.

In one embodiment of the invention, the purification comprises a two phase partitioning system. In a further embodiment of this invention, the two phase partitioning system uses a polar solvents (one or combinations) including, but is not limited to water, C₁-C₄ alcohol (e.g. methanol, ethanol, isopropanol, butanol), dimethyl sulfoxide, tetrahydrofuran, acetone, acetonitrile, and a non-polar solvents (one or combinations) such as, but no limited to hexanes, heptanes, ethyl ether, ethyl acetate, petroleum ether, chloroform, toluene, methyl tert-butyl ether, methyl isobutyl ketone and mixtures therein. See e.g. Alain P. Foucault, L. Chevolot. *Counter-current chromatography: instrumentation, solvent selection and some recent applications to natural product purification*. J. Chromatogr. A 808 (1998) 3 –22.


In another embodiment of the invention, the solvent system for the two phases partitioning system include, but is not limited to is methanol : heptane and/or water : hexane and/or water : butanol and/or methyl tert-butyl ether: acetonitrile : water, and/or heptanes : ethyl acetate: acetonitril, heptanes : ethyl acetate : methanol : water (at different ratios) of alone or in parallel to enrich the activity in one of the phases.

Another embodiment of the purification process is a partitioning separation comprising Fast or High Performance Centrifugal Partition Chromatography (FCPC or HPCPC) or Countercurrent chromatography (CCC). to separate the compounds based on their corresponding partition coefficient with the aim of reducing and/or eliminating contaminants obtained during the extraction. See e.g. Alain P. Foucalt. *Centrifugal Partition Chromatography*, Chromatographic Sciences Series, vol. 68, Marcel-Dekker (1995). The purification process by CPC can increase the concentration of naturally occurring antimicrobial compounds from avocados (more than 4-fold), that inhibit the growth of vegetative cells and spores of gram positive bacteria, to provide at least 1.2 to 2 times or greater antibacterial properties when compared to an acetone crude extract from avocado seed evaluated at the same concentration of solids (2.5 mg/mL).

In another aspect of the invention, the extraction and purification process optionally does not result in saponification of the enriched or isolated compounds. In another embodiment of this aspect of the invention, the extraction and purification process optionally does not result in saponification of the enriched or isolated compounds.

The extracts of the invention contain compounds with m/z in the range of 329 to 381 or at least one of the following acetogenins: Persenone A, Persenone B or the newly discovered (2*R*,5*E*,16*E*)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-5,16-diene or the also newly discovered (2*R*, 16*E*)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-16,18-diene that can be purified from *Persea americana* or chemically synthetized to enrich the bioactivity.

Another aspect of the invention is a compound of formula (I)



wherein

R^1 is hydrogen or acetyl;

R^2 is hydrogen or a hydroxy protecting group; and

R^3 is an alkenyl group with at least two carbon-carbon double bonds with trans (*E*) configuration.

The hydroxy protecting group can be any known hydroxy protecting group, e.g. those described in Greene and Wuts, *Protective Groups in Organic Synthesis (Third Edition)*, Wiley-Interscience (1999). As noted above, the compounds of formula (I) include all stereoisomeric forms which includes (*R*) and (*S*) forms and cis (*Z*) and trans (*E*) forms of the compounds. For the purposes of this invention, the trans (*E*) form can include a terminal alkene which has the formula $-CH=CH_2$ (see e.g. (2*R*, 16*E*)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-16,18-diene below).

One embodiment of this aspect of the invention are compounds of formula (I) wherein,

R^1 is hydrogen or acetyl;

R^2 is hydrogen or a hydroxy protecting group; and

R^3 is an C_5 - C_{22} alkenyl group with two carbon-carbon double bond trans configuration.

Another embodiment of this aspect of the invention are compounds of formula (I) wherein,

R^1 is hydrogen or acetyl;

R^2 is hydrogen; and

R^3 is an C_5 - C_{22} alkenyl group with two carbon-carbon double bond with trans configuration.

Another embodiment of this aspect of the invention are compounds of formula (I) wherein,


R^1 is acetyl;

R^2 is hydrogen; and

R^3 is an alkenyl group comprised of 12 to 18 C atoms, with two carbon-carbon double bond with trans configuration; and the carbon which is bonded to OR^2 is in the (*R*)-configuration.


Another embodiment of this aspect of the invention are compounds of formula (I) wherein, there is a double bond at the C-16 and C-17 position of the compound.

Another embodiment of this aspect of the invention are compounds which have the formula



(2R, 16E)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-16,18-diene

or



(2R, 5E, 16E)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-5,16-diene

The compounds of formula (I) can be synthesized by reacting dimethyl-1,3-dioxolane-ethylmagnesium halide (e.g. chloride or bromide) with a reagent of the formula R^3COX wherein R^3 is as defined above and X is a halide and subsequently forming a diol from the dioxolane ring using the procedures described in Bull et al. (1994).

Alternatively, the compounds of formula (I) can be synthesized by obtaining an unsaturated fatty acid and converting it to its corresponding methyl ketone and then reacting the corresponding methyl ketone with 2-acetoxyacetaldehyde using the procedures described in MacLeod et al. (1995).

The methods of forming the compounds of formula (I) are intended to be illustrative in nature and is not intended to encompass all possible means of making the compounds.

The extracts or compounds can be used in foods or compositions that support the growth of bacteria, alone or in combination with other antimicrobial substances commonly known in the art which include but are not limited to nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, essential oils, ethylenediaminetetraacetic acid (EDTA) and ascorbic acid derivatives, benzoic acid derivatives, among others in order to improve the antimicrobial activities against the growth of vegetative and sporulated states of bacteria. The avocado extract or compounds or extracts derived therefrom inhibit the growth of vegetative and sporulated forms of bacteria can be formulated in solid form, with carriers, excipients, encapsulating agents and other formulation components to improve the application and stability of the bioactive components.

The extracts, compounds and compositions of the invention are prepared so that they may be administered orally, dermally, parenterally, nasally, ophthalmically, otically, sublingually, rectally or vaginally. Dermal administration includes topical application or transdermal administration. Parenteral administration includes intravenous, intraarticular, intramuscular, and subcutaneous injections, as well as use of infusion techniques. One or more compounds of the invention may be present in association

with one or more non-toxic pharmaceutically acceptable ingredients to form the composition. These compositions can be prepared by applying known techniques in the art such as those taught in Remington – The Science and Practice of Pharmacy, 21st Edition (2005), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition (2005) and Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (8th Edition), edited by Allen et al., Lippincott Williams & Wilkins, (2005).

Another aspect of the invention are food products which comprised of the extracts or compounds of the invention which include, but are not limited to fish, crustaceans, fish substitutes, crustacean substitutes, meat, meat substitutes, poultry products, vegetables, greens, sauces, emulsions, beverages, juices, wines, beers, dairy products, egg-based products, jams, jellies, grain-based products, baked goods and confectionary products.

Another aspect of the invention are cosmetic products which comprise of the extracts or compounds of the invention which include, but are not limited to products such as creams, gels, powders, lotions, sunscreens, lipstick, body wash, herbal extracts, and formulations that support the growth of bacteria.

Another aspect of the invention are products with a surface which comprise of the extracts or compounds of the invention which include, but are not limited to counter tops, doors, windows, handles, surgical equipment, medical tools, contact surfaces that can contaminate humans, animals, etc.

Another aspect of the invention is the use of the extracts or isolated compounds of the invention or compositions comprising the same to provide an antibacterial, antimicrobial or sporicidal effect to a patient in need thereof.

Another aspect of the invention is the use of the extracts or isolated compounds of the invention or compositions comprising the same to provide an antibacterial, antimicrobial or sporicidal effect to a food or cosmetic composition.

Another aspect of the invention is the use of the extracts or isolated compounds of the invention or compositions comprising the same to provide an antibacterial, antimicrobial or sporicidal effect to a surface. The effect may be produced by exposing the surface with the extracts or isolated compounds of the invention or by laminating or embedding the extracts or isolated compounds of the invention onto the surface itself.


The antimicrobial, antibacterial and/or sporicidal effect can be applied to microorganisms, bacterias or other spore-forming microorganisms from the genera which include, but is not limited to *Clostridium*, *Bacillus*, *Alicyclobacillus*, and *Listeria*.

The antimicrobial, antibacterial and/or sporicidal effect can be applied to microorganisms, bacteria or spores from the list of species which includes, but is not limited to *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus subtilis*, *Bacillus licheniformis*, *Alicyclobacillus acidoterrestris*, *Alicyclobacillus acidiphilus*, *Listeria monocytogenes*.


The novel compounds from the extract and purification of the invention were depicted above in Formula (I). For the purposes of providing an antimicrobial, antibacterial and/or sporicidal effect, the compounds

of Formula (I) can have as few as one carbon-carbon double bond for R^3 and this double bond can either be in the cis (*Z*) or trans (*E*) configuration. One embodiment of this scope of the compounds of Formula (I) is that the carbon-carbon double bond are at C-5/C-6, C-12/C-13, C-15/C-16, C-16/C-17 or any combination thereof, with the bonds being trans or cis bonds. Another embodiment of the scope of the compounds, include where the carbon-carbon double bond is at C-5 and C-6 alone, and/or C-16 and C-17, and/or C-12 and C-13, and/or C-15 and C-16 positions, either being trans or cis bonds.

Examples of this enhanced scope of the compounds of formula (I) include, but are not limited to:




(2*R*, 5*E*, 12*Z*, 15*Z*)-1-acetoxy-2-hydroxy-4-oxo-heneicosa-5, 12, 15-triene (Persenone A)




(5*E*)-1-acetoxy-2-hydroxy-5-nonadecen-4-one (Persenone B)

or



(2*R*, 12*Z*, 15*Z*)-1-acetoxy-2-hydroxy-4-oxo-heneicosa-12, 15-diene (Persin)

Moreover, for the purposes of providing an antimicrobial, antibacterial and/or sporicidal effect, the compound of Formula (I) can be used alone or in combination with the compounds for formula (II) depicted below:



wherein

R^1 is hydrogen or acetyl;

R^2 and R^4 hydrogen or a hydroxy protecting group; and

R^3 is an alkenyl group with at least one carbon-carbon double bond.

One embodiment of this aspect of the invention are compounds of formula (II) wherein,

R^1 is hydrogen or acetyl;

R^2 and R^4 is hydrogen or a hydroxy protecting group; and

R^3 is an C_5 - C_{22} alkenyl group with one carbon-carbon double bond with cis and/or trans configuration.

Another embodiment of this aspect of the invention are compounds of formula (II) wherein,

R^1 is hydrogen or acetyl;

R^2 and R^4 is hydrogen; and

R^3 is an C_5 - C_{22} alkenyl group with two carbon-carbon double bond with trans configuration.

Another embodiment of this aspect of the invention are compounds of formula (II) wherein,


R^1 is acetyl;

R^2 and R^4 is hydrogen; and

R^3 is an alkenyl group comprised of from 12 to 18 C atoms, with one carbon-carbon double bond with trans configuration; and the carbon which is bonded to R^2 and R^4 is in the (S)-configuration.

Another embodiment of this aspect of the invention are compounds of formula (II) wherein, there is a double bond at the C-16 and C-17 position of the compound.

Another embodiment of this aspect of the invention is use of the compound of formula (II) depicted below:



(2S, 4S)-1-acetoxy-2,4-dihydroxy-*n*-heptadeca-16-ene

The compounds of formula (II) can be synthesized via reduction of ketone from the compounds of Formula (I) or synthesized by reacting dimethyl-1,3-dioxolane-4-ethanal with a compound of R^3MgX wherein R^3 is as defined above and X is a halide using procedures disclosed by Sugiyama et al. (1982).

In another aspect of the invention, the antibacterial, antimicrobial or spostatic/sporicidal effects are at least as effective as other known antibacterial, antimicrobial or spostatic/sporicidal agents such as LAE (ethyl ester of lauramide of arginine monohydrochloride), nitrites or nisin (a polycyclic peptide with 34 amino acids). Use of the extracts or isolated compounds of the invention being a natural product or easily derived therefrom is advantageous over other known agents which are either not natural products or are not easily obtained. The use of non-natural products especially has ramifications when making food or cosmetic products which may require regulatory approval for their use.

The invention is further described by the following non-limiting examples which further illustrate the invention, and are not intended, nor should they be interpreted to, limit the scope of the invention.

EXAMPLES

Example 1 – Antimicrobial and sporicidal activity of acetone and hexane avocado seed extracts

Avocado seeds were ground using a colloidal mill to obtain particles with an average radius of 0.5-2 mm. Ground avocado seeds (50 g) were mixed with either acetone or hexane at a material-to-solvent ratio of 1:2 (w/v). Mixtures were stored for 24 hr at 25°C in order to obtain an avocado seed raw extract. The seed was separated from the extract by means of vacuum filtration. The raw extracts were evaporated under vacuum to dryness using a rotary evaporator (35°C, 22 in Hg) and the obtained dry matter was weighed and redissolved in acetone to a final concentration of 2.5 mg/ml. Adjusted samples were used for antimicrobial and sporicidal tests (see **Figure 1**).

For the antibacterial evaluations, adjusted solutions (5 μ L) were transferred to sterile 6-mm diameter discs made from Whatman no. 1 filter paper, so that after solvent evaporation each disc contained 12.5 μ g of solids from the enriched avocado seed extract. Experimental controls were treated under the same conditions that the extracts and included negative control discs that contained 5 μ L of acetone, and for positive control discs 5 μ L of a nisin solution (30 mg/ml in sterile water) were added to provide a residual concentration of 150 μ g of nisin in each disc. All test discs were left for about 1-2 hr in a Biological Safety Cabinet to evaporate the solvent. Suspensions of about 0.1 optical density (at 600 nm) containing approximately 1 to 2 x 10⁸ CFU/ml of *Clostridium sporogenes* (ATCC 7955) vegetative cells, isolated native spores or isolated heat shocked spores were prepared as described in official protocols of Health Canada (Food Directorate, 2010). Aliquots of the suspensions (100 μ L) were transferred to Petri dishes containing 15 ml of solid medium (TPGY medium) and spread evenly with a sterile plastic rod. Four discs, each containing 12.5 μ g of the test extract, and two more discs (one solvent blank and one nisin positive control) were placed each dish and incubated at 37°C under anaerobic conditions. The diameter of the inhibition zones (cm) around the discs were measured after 36 hrs.

Acetone and hexane avocado seed extracts showed significant antimicrobial activity against vegetative bacterial cells, as well as native and heat-shocked spores of the spore forming bacteria *Clostridium*

sporogenes (see **Figure 2**). Non- significant differences between the activity of acetone and hexane extracts was observed, except for heat shocked spores where the hexane extract showed around 20% higher sporicidal activity than the acetone extract. Both acetone and hexane avocado seed extracts presented higher antibacterial activities than the positive control (nisin, 150 µg). Positive control treatments (nisin) gave inhibition zones of 1.3, 1.0 and 0.9 cm for vegetative bacterial cells, spores and heat shocked spores, respectively.

Avocado seeds used to obtain the crude extracts, once ground, can be stored at temperatures below 25°C in presence or absence of oxygen for at least 14 days without affecting the antibacterial activity against spore forming bacteria. Therefore avocado seeds can be stored as a whole or as a meal prior to the preparation of the extracts enriched in bioactive compounds.

Example 2- Specific activity of avocado seed extracts against vegetative cells and heat-shocked bacterial spores of spore-forming bacteria as compared to other plant sources.

The efficacy of the present invention can be observed by the preparation of crude antibacterial extracts from mango seed kernel, which has been reported in the prior art to exhibit antibacterial activity against vegetative cells of spore-forming bacteria (Kabuki et al., 2000).

Crude extracts from avocado (*Persea americana*) and mango kernel (*Mangifera indica*) were prepared as described in Example 1 and their antibacterial activities tested against the growth of vegetative cells and heat-shocked spores of *C. sporogenes* (See **Table 1**).

Table 1. Antibacterial activities of avocado seed and mango kernel extracts against vegetative cells and heat shocked spores of *Clostridium sporogenes* (ATCC 7955).

Plant Source	Extract Concentration (mg/mL)	Antibacterial Activity against <i>Clostridium sporogenes</i> (Disc inhibition zone (cm))	
		Vegetative cells	Heat-shocked spores
Avocado Seed (<i>Persea americana</i>)	2.5 (acetone extract)	2.0	1.0
	1.25 (acetone extract)	1.4	1.0
Mango Seed Kernel (<i>Mangifera indica</i>)	100 (hexane extract)	0.7	0.0
	250 (hexane extract)	1.0	0.0
	100 (acetone extract)	0.0	0.0
	250 (acetone extract)	0.0	0.0
Nisin (positive control)	40	1.0	0.9
	2.5	0.0	0.0
Methanol (negative control)	0.0	0.0	0.0

Contrary to the expected only the avocado seed extracts presented activity against the two bacterial physiological stages tested herein, vegetative cells and heat shocked spores. Mango kernel extracts

presented antibacterial activity against vegetative cells of spore forming bacteria but not against the growth of bacterial spores or heat-shocked spores.

The present example therefore demonstrates that the chemical nature of avocado phytochemicals is particularly useful for the inhibition of the growth of vegetative cells, spores and heat-shocked pores of spore-forming bacteria.

Example 3 – Effect of shaking on the antimicrobial activities of crude acetone and hexane avocado seed extracts

Similarly to Example 1, avocado seeds were ground using a colloidal mill obtaining particles with an average diameter of 0.5-2 mm. Ground avocado seeds (50 g) were mixed with hexane at a material-to-solvent ratio of 1:2 (m/v). Mixtures were shaken or soaked at 200 rpm for 24 hr at 25°C in order to obtain an avocado seed raw extract. The raw extracts were evaporated to dryness using a Rotary evaporator (35°C, 22 in Hg) and the obtained dry matter was weighed.

As in **Example 1**, dry matter was re-dissolved in acetone to a final concentration of 2.5 mg/ml for the antibacterial evaluations. *Clostridium sporogenes* (ATCC 7955) was used as test microorganism since it is a known surrogate microorganism for *Clostridium botulinum*. Antimicrobial activities against vegetative bacterial cells, as well as native and heat-shocked spores were conducted as described in **Example 1**.

A significant effect was observed for the shaking treatment on the antimicrobial properties of the avocado seed hexane extract against vegetative bacterial cells, native spores and heat shocked spores (**Figure 3**). Extracts obtained without shaking presented a higher antibacterial activity when compared with those obtained with shaking, even though the yields of extracted dry mass are higher when shaking. Through the example we can observe that shaking enhances the extraction of other non-antimicrobial compounds present in the avocado seed, therefore diluting the concentration of compounds with antibacterial activity. Therefore, the antibacterial avocado seed extract must be obtained by maceration, preferently without shaking.

Due to the dilution of compounds, the extract obtained with shaking gave similar or lower inhibition zones than the positive control (nisin, 150 µg) which showed 1.3, 1 and 0.9 cm for vegetative cells, spores and heat shocked spores, respectively.

Example 4 – Effect of extraction time and extraction solvent type (acetone, ethanol and hexane) on the antimicrobial properties of crude avocado seed extracts.

Avocado seeds were ground using a colloidal mill obtaining particles with average radio of 0.5-2 mm. Ground avocado pits (50 g) were mixed with either acetone or ethanol or hexane at a material-to-solvent ratio of 1:2 (m/v). Mixtures were shaken at 200 rpm 24 hr at 35°C in order to obtain an avocado seed crude extracts. Aliquots from each crude extract were sampled at times 0.5, 5 and 24 hr during extraction. Crude extracts obtained at different extraction times were evaporated to dryness using a Rotary evaporator (35 °C, 22 in Hg) and the obtained dry matter was weighed.

Dry matter was re-dissolved in acetone to a final concentration of 2.5 mg/ml. *Clostridium sporogenes* (ATCC 7955) was used as test microorganism in the antimicrobial assays. Antibacterial activities against vegetative cells, native spores and heat shocked spores (using the disc inhibition zone determination) were conducted as described in **Example 1**.

Antimicrobial activities of hexane extracts against vegetative bacterial cells, spores and heat-shocked spores were considered as a 100% inhibition for comparison purposes with the other solvents (acetone and ethanol) at the same time interval. Results of the antibacterial activity against vegetative cells are shown in **Figure 4** and indicated that an ethanol extract obtained after an extraction time of 30 minutes had exactly the same activity as the one obtained with hexane under the same conditions. In contrast at an extraction time of 30 min with acetone the extract presented only 70% of the antimicrobial activity observed for the hexane extract, value that reached a maximum of antimicrobial activity of 80% of the activity observed in hexane extract after an extraction time of 5 hrs. Therefore this example demonstrates that since acetone and ethanol are polar solvents, increasing the extraction time at the conditions tested diluted the concentration of bioactive compounds and/or saturated the solution. Additionally and contrary to the expected, the nature of antibacterial compounds against vegetative cells of spore forming bacteria allows a better recovery using ethanol than acetone (**Figure 4**).

The results for antimicrobial properties of the extracts against native spores are presented in **Figure 5**; and indicated that increases in extraction times (0.5 – 24 hr) did not present any differences using either solvent acetone or ethanol as the extraction solvents. Ethanol also was more selective for the extraction of the compounds with antibacterial properties against native spores.

Results for the antimicrobial activities of the different extracts against the growth of heat-shocked spores are presented in **Figure 6**, and indicated a different trend, at 30 min of extractions both solvents (acetone and ethanol) were equally efficient for the extraction of the antibacterial molecules. However, when acetone was used as solvent over time a significant decrement on the concentrations of antibacterial molecules in the extracts was observed that varied from 100% to less than 80% bacterial inhibition for extraction times of 0.5 to 5 hr, respectively, and then the activity remained constant. Ethanol did not get as easily saturated over the extraction time with the compounds of interest as the acetone extract did and therefore, for this solvent, no differences were observed for the extraction times between 0.5 and 5 hours. Therefore the present example demonstrates that ethanol was as effective as hexane for the extraction of the antimicrobial compounds with inhibitory activities against the growth vegetative cells, native spores and heat-shocked spores from spore forming bacteria.

Example 5 – Comparison of the fractionation of an acetone avocado seed extract versus ground avocado seeds in heptane: methanol two-phase non-miscible solvent system

For the present example an acetone raw extract of avocado seed was obtained as described in Example 1, and evaporated to dryness. The dry acetone raw extract obtained from 50g of ground avocado seeds was directly added to a separation funnel containing a two non-miscible solvent system comprised of 100 ml of heptane (upper phase F002) and 100 ml of methanol (lower phase F001) in order to allow the partition of polar and non-polar compounds contained in the extract (**Figure 7A**).

For comparison purposes a second two-phase system was prepared with 50 g of ground avocado seeds directly added the other non-miscible solvent system also comprised of 100 ml of heptane (upper phase) and 100 ml of methanol (lower phase). Mixture was shaken at 200 rpm 24 hr at 35°C in order to selectively extract and partition the compounds present in the seed in one step. Later, the seed was separated from the extract by means of vacuum filtration. The upper (F003) and the lower (F004) phases of this system were allowed to form in a separation funnel and were collected separately **Figure 7B**.

The different phases previously described (F001 - F004) were evaporated to dryness individually using a rotary evaporator (35 °C, 22 in Hg) and the obtained dry matter was weighed.

Dried fractions were re-dissolved in acetone to a final concentration of 2.5 mg/ml for posterior evaluation of their antibacterial activities against *Clostridium sporogenes* (ATCC 7955). Antibacterial activities against vegetative cells, native spores and heat-shocked spores (disc inhibition zone determination) were conducted as described in **Example 1**.

Results from the disc inhibition zones for heat shocked-spores indicated that a direct extraction of grounded avocado seeds with the two-non miscible solvents reduces the amount of contaminants that may migrate to the upper phase and that would dilute the effect of active compounds (**Figure 8**), therefore illustrates that is a better option for a one step isolation of compounds that inhibit spore germination. However based on the antibacterial results for the inhibition of vegetative cells both procedures resulted in similar results with no particular benefits of one over the other one.

The present example therefore demonstrates that the antibacterial substances were enriched in the upper phases of the heptane: methanol two-phase systems in both of the performed evaluations of direct extraction of the grounded seed and partitioning of a dried acetone avocado seed extract. However residual activity was also observed in the lower phases (F002 and F004), indicating that the upper phases were saturated with active compounds or that the compounds presented partial solubility in the lower phases of both systems. Therefore a subsequent extraction was set up by re-extracting the evaporated solids recovered from the lower methanol phase F002; the subsequent extraction systems (second two-non miscible solvent systems) used to recover the remaining antibacterial compounds were formed by ethyl acetate (100 mL) and water (100 mL). Antibacterial activities of the ethyl acetate and water phases are shown in **Figure 9**. This second two-non miscible solvent systems were more polar than the first ones used and no residual antibacterial activity was found in the lower phases (mainly water).

To further complete the example other two additional non-miscible solvents systems were also evaluated as alternatives, to the heptane:methanol system described above, for partitioning the dried acetone avocado seed extracts and obtaining formulations enriched in bioactive molecules. By the use of a two-phase system of hexane and methanol the antibacterial compounds were also recovered in the upper hexane phase **Figure 10**. However, the heptane:methanol two-phase system proved to be more effective for the recovery of compounds in the upper phase since it presented less migration into the lower phase. Additional tests were performed by the use of aqueous two-phase systems using water, salt and ethanol to isolate the antibacterial compounds from ethanol raw extracts and the desired compounds were recovered in the upper-phase consisting mainly of ethanol.

Example 6 – Effect of saponification on the antimicrobial activities of acetone and hexane avocado seed extracts

Crude acetone extracts from avocado seeds were partitioned with hexane and methanol as described in Example 5. The phases were separated and the hexane rich upper phase, containing less polar compounds was evaporated to dryness using a Rotary evaporator (35 °C, 22 in Hg). According to Broutin et al (2003), saponification is a necessary step to obtain a bioactive fraction that contained aliphatic or terpenic alcohols, sterols, tocopherols, carotenoids, and xanthophylls that remain in the unsaponifiable portion and are not soluble in water. However this example demonstrates that the antibacterial compounds of the present invention could not be obtained in the same way, indicating a different chemical nature.

Saponification of the acetone raw extract and the partitioned hexane upper phase fraction was carried out according to Broutin et al (2003), with some modifications, in order to recover the unsaponifiable portion and selectively extract the furan lipids and polyhydroxylated fatty alcohols present in them. Separately, 5 g of each extract were mixed with 2.5 ml of 12N potassium hydroxide and 10 ml of ethanol then allowed to rest for 4 hours. The aqueous-alcoholic mixture was then transferred to a separations funnel and 17.5 ml of water were added, followed by addition of 17.5 ml of dichloroethane. The mixture was shaken for 30 s and then allowed to separate into two phases. The organic phase (lower phase) was recovered. This operation was repeated 6 times, and the organic phases were combined and washed with water. The dichloroethane was evaporated to dryness using a rotary evaporator (35 °C, 22 in Hg) and the obtained dry matter was weighed.

Dry matter was re-dissolved in acetone to a final concentration of 2.5 mg/ml. Antimicrobial and sporicidal activity tests (disc inhibition zone determination) were conducted as described in **Example 1**, *Clostridium sporogenes* (ATCC 7955) was used as test microorganism. As shown in **Figure 11**, only the unsaponifiables extracted from acetone raw extract showed disc inhibition on spores indicating that partitioning an acetone extract with hexane and methanol eliminates unsaponifiable compounds. Interestingly these unsaponifiable portion from the crude acetone extract had lower activity than the non-alkali treated crude acetone extract (**Figure 2**) particularly in their inhibitory activities against the bacterial spores.

Unsaponifiable compounds in the crude acetone extract had a higher specificity for vegetative cells than for spores. Partitioning with hexane-methanol reduced the activity of unsaponifiables against vegetative cells indicating that some of these compounds could migrate to the alcoholic phase during partitioning.

When the antibacterial properties of the upper hexane and lower methanol phases, in which the unsaponifiable matter from the crude acetone extract was partitioned, were compared with the activities for crude acetone and hexane extracts described in **Example 1** they were significantly lower for both phases. Results therefore indicated that active compounds are sensible to alkaline treatments or that some desirable chemical features are modified or removed during the saponification treatment and subsequent partitioning steps. Therefore, a saponification step with the aim of isolating or increasing the antimicrobial and sporicidal activity should not be considered to obtain the active avocado seed extract.

Example 7 - Partitioning chromatography of an acetone avocado seed extract.

Acetone raw extract of avocado seed was obtained and evaporated to dryness as described in **Example 1** then partitioned in a heptane:methanol two-phase system as described in **Example 5**. The upper heptane-rich phase (F001), containing less polar compounds was evaporated to dryness using a Rotary evaporator (35 °C, 22 in Hg) and then injected to a Fast Centrifugal Partition Chromatographer FCPC® Bench Scale with a 1000 ml column to fractionate the chemical compounds using heptane and methanol. The heptane was pumped into the column and it served as the stationary phase (740 mL). The methanol (mobile phase) was then pumped into the column at a flow-rate of 10 mL/min. The rotor was set at 800 rpm. The concentrated extract (65 mL), obtained from the evaporated upper phase of the heptane:methanol two-phase system in which the avocado seed acetone extract was partitioned, was injected into the FCPC after the system had reached the hydrodynamic equilibrium. Methanol was used to elute fractions during the first 170 min, and after that time heptane was used as mobile phase for 100 min. The effluent from the outlet of the column was collected in test tubes using a fraction collector set at 10 ml for each tube. An aliquot of 1 ml of each fraction was collected for antibacterial and sporostatic/sporicidal activity tests. Aliquots were evaporated to dryness using a Speed Vac concentrator, the weights of the solids from each fraction were recorded and 70 pools of consecutive fractions were formed having a final concentration per pool of 2.5 mg/ml. The antibacterial properties of each pool were assessed against vegetative cells, native spores and heat-shocked spores of *Clostridium sporogenes* as described in **Example 1**. The remaining volume from each fraction (9 mL), were evaporated to dryness using a Speed Vac concentrator, stored at 80°C and further used for chemical identification evaluations.

As can be observed in **Figure 12**, the antibacterial activity was present in the fractions with partition coefficients (K_d) lower than 0.5 (more specifically between K_d values from 0.19 to 0.35) indicating that the active compounds were at least 2 times more soluble in heptane than in methanol. Also there was a slight difference in the activity of those fractions against vegetative cells compared to spores since inhibitors of vegetative cells growth were more spread into more polar fractions.

Partitioning the extract by FCPC increased the desired antibacterial activities (up to 3 cm diameter inhibition zones) in comparison with the previous experiments with less pure extracts, clearly indicating the need to eliminate other phytochemicals that might be diluting the concentration of the antibacterial compounds (**Figure 12**). The antibacterial activities of some FCPC fractions were increased at least by 50% when compared to the data observed in **Figure 2** for the crude hexane and acetone avocado seed extracts. Results shown in **Figure 12** also demonstrate, as in **Figure 8**, that the active compounds have more affinity for the heptane phase than for the methanolic phase.

In order to further characterize the antibacterial activities of the fractions with the highest activity, it was important to determine their minimum inhibitory concentration (MIC), defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. Compared to nisin, the fractions obtained by FCPC with a K_d of 0.3 and 0.4, showed a lower MIC for vegetative cells than for the native spores or heat-shocked spores of *C. sporogenes* (**Table 2**). Fraction with K_d of 0.4 was almost 2 times more active than Nisin for spore growth inhibition but

fraction with Kd of 0.3 was about 15 times more active than Nisin. But in the case of heat-shocked spores, the differences between nisin and the fractions with Kd of 0.4 were less pronounced, but still presented the desired inhibitory properties against spore germination.

Table 2. Minimal Inhibitory Concentration (MIC) for the fractions obtained by reverse phase Fast Centrifugal Partition Chromatography (RF-FCPC) of the solids recuperated from the upper phase (heptane) of the two-phase system (heptane:methanol) used to partition an acetonic crude avocado extract as described in Example 5.

	Sample tested and Partition Coefficient (Kd)	MIC (µg/ml)
Vegetative Cells	Nisin*	5000
	Fraction with Kd of 0.4	<<78
	Fraction with Kd of 0.3	<<78
Native Spores	Nisin*	5000
	Fraction with Kd of 0.4	>> 2500
	Fraction with Kd of 0.3	312
Heat shocked spores	Nisin*	5000
	Fraction with Kd of 0.4	1250
	Fraction with Kd of 0.3	312

*Nisin was tested using initial stock solutions at 50 mg/ml and for avocado fractions at 2.5 mg/ml.

As shown in the present example, the same extract portioned by FCPC under the conditions described above (reverse phase) can also be partitioned using heptane as a mobile phase (normal phase) and results from the chromatographic separation followed the same behavior based on antibacterial activities (**Figure 13**). Therefore the first fractions obtained by FCPC had better activity than the last ones (more polar) and in **Figure 13** it is shown that antibacterial activity remained present until partition coefficient reaches 7.2, indicating that other compounds that are more than 7.2 times more soluble in heptanes than methanol do not inhibit the growth of vegetative cells or spores from *C. sporogenes*.

Example 8 - Partitioning chromatography of acetone avocado seed extract to obtain fractions with inhibitory activities against other microorganisms besides *C. sporogenes*.

Acetone raw extract of avocado seed was obtained and evaporated to dryness as described in **Example 1** then partitioned in a heptane:methanol two-phase system as described in **Example 5**. The upper heptane-rich phase, containing less polar compounds was evaporated to dryness using a Rotary

evaporator (35 °C, 22 in Hg) and then injected into a Fast Centrifugal Partition Chromatographer FCPC® using the Normal Phase conditions described in **Example 7**.

The fractions obtained from Normal phase FCPC, were then used to assess their antimicrobial activities against the growth of vegetative cells from *S. aureus* and *B. subtilis*. As can be observed in **Figure 14**, different compounds to the ones that are inhibiting *C. sporogenes* and with very low polarity are inhibiting the growth of vegetative cells of *S. aureus* and *B. subtilis* because disc inhibition zones were observed for these microorganisms when discs were inoculated with fractions of partition coefficient higher than 7, contrasting with the results of the inhibition of *C. sporogenes* shown in **Example 7**.

Table 3, summarizes the antimicrobial results from previous experiments obtained from the evaluation of the crude extracts of **Example 1**, extracts partitioned as described in **Example 5**, and unsaponifiable fractions from **Example 6**. As it can be observed, interestingly, they did not show any inhibitory effects on the growth of *S. aureus* and very low disc inhibition zones when tested against *B. subtilis* in comparison with the stronger inhibitory effects observed for the enriched CPC fractions shown in **Figure 14**.

Table 3. Evaluation of the antimicrobial activities against the growth of vegetative cells of *S. aureus* and *B. subtilis* of different crude extracts

Fraction	<i>S. aureus</i> Disc inhibition zone (cm)	<i>B. subtilis</i> Disc inhibition zone (cm)
Acetone Extract	—	0.6
Hexane Extract (shaking)	—	0.6
Hexane Extract (without shaking)	—	0.7
Upper phase (hexane) of the partitioned acetone crude extract	—	0.6
Lower phase (methanol) of the partitioned acetone crude extract	—	0.7
Unsaponifiable compounds from acetone extract	—	—
Unsaponifiable compounds from hexane-methanol partitioned acetone extract	—	—

Example 9 - Effect of high pressure and temperature on the stability of antimicrobial activity

An acetone crude extract from avocado pit was obtained and evaporated to dryness as described in **Example 1**. Then the acetone extracted avocado solids were partitioned into a two-phase hexane-methanol system as described in **Example 5**, followed by a [then] second partitioning system of ethyl acetate:water used to completely recover the active compounds present in the lower phase (methanol) phase of the first partitioning system (also described in **Example 5**). The hexane and the ethyl acetate

phases were recovered separately and evaporated to dryness using a Rotary evaporator (35 °C, 22 in Hg). Both phases were then filled in vials and exposed to high hydrostatic pressure (HHP) treatments of 300 MPa and 600 MPa (43,511 and 87,022 psi, respectively), during 3 and 6 minutes. No significant difference was observed in the antibacterial properties of the extracts after the high pressure treatments, indicating that the compounds responsible for the observed antimicrobial properties are stable to HHP treatments.

The thermal stability of the active compounds was also tested at temperatures that ranged from 25 to 100°C for 60 min. The compounds with activity against the growth of vegetative cells of *C. sporogenes* were the less sensitive to thermal treatment (**Figure 15**) than those responsible for the inhibitory properties against the growth of native spores (**Figure 16**). As it can be observed in **Figure 15** the inhibitory properties against vegetative cells were decreased by 20 and 23.5%, after a treatment of 100°C for 60 minutes of the ethyl acetate and hexane extracts, respectively, and in reference to the inhibitory properties of non-heated control extracts maintained at 25°C.

Heat shocked spores were more resistant to the action of the thermally treated hexane and ethyl acetate crude extracts; the inhibitory properties against heat-shocked spores were decreased by 50%, after exposure of the extracts to 100°C for 60 minutes, and in reference to the inhibitory properties observed for the control extracts maintained at 25°C.

Example 10 - Identification of the main compounds found in bioactive fractions

The fractions with the highest disc inhibition zones (**Figure 12**), obtained by the use of reverse phase Fast Centrifugal Partition Chromatography (RP-FCPC), and that had a K_d between 0.19 -0.35 were mixed together in order to form a “pool of active fractions”, as described in Example 7. Initially the fractions (13) were adjusted at the same concentration of 192.3 mg/ml and equal volumes of each of them (100 µl) were taken and adjusted with ethanol to a final concentration of 50 mg/ml.

Figure 17 shows the progressive change in the chromatographic profiles of the fractions present in the active pool, as their K_d increases. Evaporated aliquotes of individual fractions were adjusted to 1 mg/ml with HPLC grade methanol and 2 µl were injected. The column used was a Zorbax Extended-C18 (100 x 3 mm d.i., 3.5 µm) column. The mobile phases included water 100% as phase A and methanol 100% as phase B. The solvent gradient used is described in **Table 4**, pumped at a flow rate of 0.38 ml/min and a post equilibration time of 6 mins. The detector was set at a wavelength of 220 nm.

Table 4. Solvent Gradient used to achieve the chromatographic separation of the fractions collected after fast centrifugal partition chromatography (A= water and B=Methanol).

Time (min)	%A	%B
0	30	70
4	15	85
22	10	90
24	0	100
26	0	100

The typical chromatograph obtained for the active pool of antimicrobial compounds from avocado is shown in **Figure 17**. The numbers indicated in the chromatogram represent the common peaks that absorb at 220nm, labeled as Compounds 1 to 11, and the information on their mass and molecular formula is presented in **Table 5**. Some of these compounds have been previously reported in avocado tissues, however some of them are being disclosed herein as new chemical compounds since they were discovered by the inventors in the antimicrobial fractions. In most of the bioactive fractions, compounds such as 1, 2, 4 and 11 were in lower concentrations when compared to compounds 7 and 9 (**Figure 17**).

Table 5. Chemical characterization of the compounds found in the antimicrobial fractions.

Peak Number (Common name) ^a	[M+H] ⁺ Molecular Formula	Reference
Compound 1	347.2279	None
Compound 2	349.2418	None
Compound 3	329.2708 C19H36O4	Néeman et al. 1970, Bittner et al. 1971 Brown 1972, Prusky et al. 1991b
Compound 4	329.2816 C19H36O4	Kashman et al. 1969, Bittner et al. 1971, Brown 1972
Compound 5	353.2706 C21H36O4	None New compound
Compound 6	353.2708 C21H36O4	None New compound
Compound 7 (Persenone A)	379.2864 C23H38O4	Domergue et al., 2000, Kim et al., 2000a
Compound 9A (Persenone B)	355.2865 C21H38O4	Kim, 2000a, 2000b and 2000c
Compound 9B (Persin)	381.3022 C23H40O4	Prusky et al. 1982, Oelrichs et al., 1995 Sivanathan and Adikaram, 1989, Domergue et al., 2000

^a Common name, where applicable

Example 11 - Evaluation of sporostatic and sporicidal activity of a fraction enriched in antimicrobial compounds.

In order to demonstrate that the pool of active fractions described in **Example 10** (partition coefficient 0.19-0.35) had sporostatic or sporicidal activity, it was necessary to determine its minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC). In general terms, MIC is defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. While the MBC is the lowest concentration of the antimicrobial that will prevent the growth of a microorganism after subculture to fresh agar media free from the antibiotic or antimicrobial agent. The pool of active the fractions was tested at concentrations ranging from 0.005 to 2.5 mg/ml and nisin was used as control.

Table 6 shows that the pool of active fractions was much better than nisin as an inhibitor of the growth of spores from *C. sporogenes* since its MIC is almost one tenth of that obtained for nisin. According to

Smola (2007), if the ratio of the MBC/MIC ≤ 4 , the compound can be considered as sporocidal and if the ratio of the MBC/MIC > 4 , it is only sporostatic. In this example, both nisin and the pool of avocado active fractions presented a sporocidal effect.

Table 6. Minimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC) and MBC/MIC ratio, for nisin and the pool of active fractions isolated from avocado seed, against the growth of heat shocked spores from *C. sporogenes*.

Sample	MIC ($\mu\text{g/ml}$)	MBC ($\mu\text{g/ml}$)	MBC/MIC ^a
Nisin	234	156	1.5
Pool of active fractions	19.5	19.5	1

^a Ratios of the MBC/MIC ≤ 4 indicate sporocidal activity. Ratios of the MBC/MIC > 4 indicate sporostatic activity.

Example 12 – Antimicrobial activities of isolated chemical compounds from bioactive fractions

In this example, the antimicrobial activities of the same isolated compounds described in **Example 10 (Table 5)** were tested against the growth of vegetative cells and heat shocked spores of *C. sporogenes*, and on vegetative cells of *S. aureus*, *P. aeruginosa*, *E. coli*. and *B. subtilis* as previously described in Example 1, and at a concentration of 0.5 mg/ml. As it can be observed in **Table 7**, compound 6 (peak 6) and persenone B (peak 9A) demonstrated greater antimicrobial properties when tested against *C. sporogenes*, followed by persenone A (peak 7). Additionally, from all the bioactive compounds, only persin (peak 9B) showed a lower activity than nisin, although nisin a known antimicrobial was tested at a 100-fold higher concentration. Since it has been reported that persin is able to inhibit fungi spore germination (Prusky et al., 1982), and in the present experiment it seems to have the lowest activity, it can be assumed that the other bioactive compound would have a higher activity against fungi spore.







Table 7. Evaluation of the antimicrobial activities of the active isolated compounds from Figure 17 against the growth of vegetative cells and heat shocked spores of *Clostridium sporogenes* (ATCC 7955).

Peak number	Common name	Disc Inhibition Zone (cm)	
		Vegetative Cells	Heat Shocked Spores
Compound 3		1.1	1.0
Compound 5		1.0	1.1
Compound 6		1.9	1.7
Compound 7	Persenone A	1.6	1.5
Compound 9A	Persenone B	1.9	1.7
Compound 9B	Persin	1.0	0.6
Negative Control		0.0	0.0
Positive Control (nisin at 50 mg/ml)		1.1	1.0

It is important to remark that, to our surprise, all the compounds showing the highest activity against vegetative cells and heat shocked spores of *C. sporogenes* (Compound 6, Persenone B y Persenone A

mentioned from the highest to the lowest antimicrobial activities reported in **Table 7**) contained a C5-C6 double bond (see **Table 8**). Moreover, if the structures of the persin (compound 9B) and persenone A (compound 7) are compared, the only difference is the lack of the C5-C6 double bond in persin (compound 9B), and in this example we demonstrate that its antimicrobial activity was reduced by 37.5%. Additionally, the only structural difference between persenone B (compound 9A) and compound 6 is that the later also presents a C16-C17 double bond, but their inhibitory activities were the same. This observation also supported the finding that a C5-C6 double is a desirable structural feature to improve the antimicrobial activities of the compounds described herein, and that the C16-C17 double bond is also a preferred structural feature, since it is the only unsaturation present in compound 3, and it had a higher activity than persin (compound 9B) that contains two insaturations and none between C16-C17.

Table 8. Chemical structures and common names of the compounds responsible of the antimicrobial activities of avocado seed.

Peak/ Compound Number (Common name)	Chemical structure Name
Compound 3	 (2 <i>S</i> , 4 <i>S</i>)-1-acetoxy-2,4-dihydroxy- <i>n</i> -heptadeca-16-ene
Compound 5	 (2 <i>R</i> , 16 <i>E</i>)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-16,18-diene
Compound 6	 (2 <i>R</i> , 5 <i>E</i> , 16 <i>E</i>)-1-acetoxy-2-hydroxy-4-oxo-nonadeca-5,16-diene
Compound 7 (Persenone A)	 (2 <i>R</i> , 5 <i>E</i> , 12 <i>Z</i> , 15 <i>Z</i>)-1-acetoxy-2-hydroxy-4-oxo-heneicosa-5, 12, 15-triene
Compound 9A (Persenone B)	 (5 <i>E</i>)-1-acetoxy-2-hydroxy-5-nonadecen-4-one
Compound 9B (Persin)	 (2 <i>R</i> , 12 <i>Z</i> , 15 <i>Z</i>)-1-acetoxy-2-hydroxy-4-oxo-heneicosa-12, 15-diene

The most antibacterial compounds against *C. sporogenes* (Compound 6, Persenone B and Persenone A) did not show inhibitory activity against *S. aureus*, *P. aeuroginosa* or *E. coli* (**Table 9**), but compound 6 also presented the greatest inhibitory activities against the growth of *B. subtilis*, followed by persenone A. Since Compound 6 is a newly discovered compound that was not previously reported as an avocado constituent, there are not previous reports of its antimicrobial or any other biological activity. Persenone A had been previously reported as antifungal but according to the results of **Table 7**, its antibacterial activity is specific to spore forming gram positive bacteria. The pool of active fractions obtained as described in **Example 10**, and that presented antibacterial properties against *C. sporogenes* in Example 10, in the present example only resulted in inhibitory properties against the spore forming bacteria *B. subtilis*.

Table 9. Disc inhibition zones of the bioactive compounds and the pool of active fractions for vegetative cells and *B. Subtillis*, *S. aureus*, *P. aeuroginosa* and *E. coli*

Peak/Compound Number (Common name)	Antibacterial Activity (Disc inhibition zone (cm))			
	<i>B. Subtillis</i>	<i>S. aureus</i>	<i>P. aeuroginosa</i>	<i>E. coli</i>
Compound 6	1.3	0.0	0.0	0.0
Compound 7 (Persenone A)	0.7	0.0	0.0	0.0
Compound 9A (Persenone B)	0.0	0.0	0.0	0.0
Pool of active fractions	0.9	0.0	0.0	0.0

The MICs for Compound 6, Persenone B (Compound 9A) and Persenone A (Compound 7) was determined against the germination of heat shocked spores from *C. sporogenes* as described in **Example 11**. As can be seen in **Table 10**, the three compounds had MICs values 15-30 fold lower than nisin, demonstrating their efficacy against bacterial spores. The MIC for the pool of active fractions was 19.5 µg/ml (**Example 11**) and it was reduced to 7.8 µg/ml for persenone A and persenone B when isolated, but the antimicrobial properties for Persenone B within the pool did not corresponded to its lower concentration since it contained less µg of that compound but when combined with the other bioactive molecules its activity appears to be potentiated. Interestingly, isolated compounds presented only sporostatic activity against *C. sporogenes* and did not showed the sporocidal bioactivity that was observed for the pool of active fractions (**Table 6**).

Table 10. Minimum Inhibitory Concentrations (MIC), for nisin, Compound 6, Persenone B y A, against heat shocked spores from *C. sporogenes*.

Peak/Compound Number (Common name)	MIC (µg/ml)
Compound 6	15.6
Compound 7 (Persenone A)	7.8
Compound 9A (Persenone B)	7.8
Nisin	234

Example 13 - Antibacterial activities of avocado seed extracts combined with refrigeration temperatures for the control of *Listeria monocytogenes*.

The pool of active fractions described in **Example 10** also presents antibacterial effects against cold-stressed vegetative cells of gram positive bacteria capable of growing under refrigerated conditions, such as *Listeria monocytogenes*. At the optimum growth temperature of 37°C for *Listeria monocytogenes* the avocado pool extract enriched in bioactive acetogenins was not particularly useful for the inhibition of the growth of vegetative cells of the tested organism (**Table 11**). Contrary to the expected we found that the avocado seed pool extract was particularly useful for inhibiting the growth of *Listeria monocytogenes* under refrigerated conditions. Furthermore, in **Table 12** we illustrate that when the antibacterial activities of the avocado acetogenins isolated in the present invention, were tested against the growth of vegetative cells of *Listeria monocytogenes*, the compounds presenting the desirable feature of a double bond between C5 and C6 can be used for the control of *Listeria monocytogenes* in foods and biological matrixes stored under refrigerated conditions.

Table 11. Antibacterial activities of avocado seed extracts combined with low temperatures of storage against the growth of vegetative cells of *Listeria monocytogenes*.

Antibacterial Substance	Extract Concentration (mg/mL)	Antibacterial activity against vegetative cells of <i>Listeria monocytogenes</i> (Disc inhibition zone (cm))	
		Incubation Temperature (4°C)	Incubation Temperature (37°C)
		Storage Time (17 days)	Storage Time (48 hours)
	50	1.0	0.0

Avocado Seed (<i>Persea americana</i>)	25	1.1	0.0
	12.5	1.1	0.0
	6.25	0.0	0.0
	3.125	0.0	0.0
Nisin (positive control)	40	2.5	1.1
Methanol (negative control)		0.0	0.0

Table 12. Antibacterial activities of the isolated avocado compounds combined with refrigeration against the growth of vegetative cells from *Listeria monocytogenes*.

Peak/Compound Number (Common name)	Concentration (mg/ml)	Antibacterial Activity (Disc inhibition zone (cm))	
		4° C	37° C
		20 days	48 hours
Compound 3	0.5	0.0	0.0
Compound 5	0.5	0.0	0.0
Compound 6	0.5	1.1	0.0
Compound 7 (Persenone A)	0.5	1.1	0.0
Compound 9A (Persenone B)	0.5	1.0	0.0
Compound 9B (Persin)	0.5	0.0	0.0
Nisin (positive control)	40	2.6	1.1
MeOH (negative control)		0.0	0.0

Example 14- Quantification of the antimicrobial compounds in enriched avocado extracts

The concentration of the antibacterial compounds present in the pool of active fractions described in **Table 7 (Example 10)** is presented in **Figure 18**. Persenone A represents 36.32% of the dry weight of the pool of active fractions, persenone B was only 0.20% and compound 6 accounts for the lowest amount (0.05%). It seems that the other components in the mixture do not affect the inhibitory activity of Persenone A, and therefore no further purification may be needed.

Table 13 shows that there is a very similar concentration of the most bioactive compounds against *C. sporogenes* (Compound 6, Persenone B and Persenone A) in fresh avocado pulp and seed, being Persenone A the most concentrated. The information of this example is relevant because if the bioactive compounds are also present on the pulp they can be easily obtained from other parts of the fruit. The present example also demonstrates that humans are being exposed to the bioactive molecules, when eating the fruit, at the concentrations required for achieving their antibacterial properties; therefore establishing their commercial potential in the food, medical and cosmetic arts.

Table 13. Concentrations of Compound 6, Persenone B and Persenone A in fresh avocado pulp and seed (ug/g of fresh weight).

Compound	Avocado Pulp (ug/g of fresh weight)	Avocado Seed (ug/g of fresh weight)
Compound 6	18.59 ± 2.30	19.11 ± 3.45
Compound 7 (Persenone A)	74.86 ± 4.75	63.32 ± 6.34
Compound 9A (Persenona B)	42.42 ± 10.22	31.89 ± 2.87

Having thus described in detail various embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

List of literature references

- Adikaram, N.K.B., Ewing, D.F., Karunaratne, A.M., Wijeratne, E.M.K. 1992. Antifungal compounds from immature avocado fruit peel. *Phytochemistry*. 31:93-96.
- AOAC Official Method 966.04 Sporicidal Activity of Desinfectants. Revised 2002.
- Baratta et al. 1998. Chemical composition, antimicrobial and antioxidant activities of laurel, sage, rosemary, oregano and coriander essential oils. *J. Essent. Oil Res.* 10(6): 618-627.
- Beltran, J.B.U. and Bonaventura, J.S. Use of cationic preservative in food products. US 7,862,842 B2. Jan 4, 2011.
- Bevilacqua, A., Sinigaglia, M., Corbo, M.R. 2008. Alicyclobacillus acidoterrestris: New methods for inhibiting spore germination. *International Journal of Food Microbiology*. 125:103-110.
- Bittner, S., Gazit, S., Blumenfeld, A. 1971. Isolation and identification of a plant growth inhibitor from avocado. *Phytochemistry*, 10(7):1417-1421

- Blackburn, P.; Gusik, S.A., Polak, J., Rubino, S.D., Nisin compositions for use as enhanced, broad range bactericides. US 5,217,950. June 8, 1993.
- Brown, B.I. 1972. Isolation of Unpleasant Flavor Compounds in the Avocado (*Persea americana*). J. Agr. Food Chem. 20:753-757.
- Bull, S.D and Carman, R.M. Synthesis of the Avocado Antifungal, (Z,Z)-2-hydroxy-4-oxohenicosa-12, 15-dien-1-yl acetate. Aust. J. Chem., 1994, 47, pp. 1661-1672.
- Burt, S. 2004. Essential oils: their antibacterial properties and potential applications in foods-a review. International Journal of Food Microbiology. 94:223-253.
- Chang, C.F., Isogai, A., Kamikado, T., Murakoshi, S., Sakurai, A., Tamura, S. Isolation and structure elucidation of growth inhibitors for silkworm larvae from avocado leaves. Agr. Biol. Chem, 1975, 39 (5), pp. 1167-1168.
- Chia, T.W.R., Dykes, G.A. 2010. Antimicrobial activity of crude epicarp and seed extracts from mature avocado fruit (*Persea Americana*) of three cultivars. Pharmaceutical Biology 48(7):753-756.
- Deans, S.G., Ritchie, G. 1987. Antibacterial properties of plant essential oils. International Journal of Food Microbiology. 5:165-180.
- Domergue, F., Helms, G.L., Prusky, D., Browse, J. 2000. Antifungal compounds from idioblast cells isolated from avocado fruits. Phytochemistry 54: 183-189.
- Food Directorate, 2010. Clostridium botulinum challenge testing of ready-to-eat foods. Food Directorate Health Products and Food Branch. Health Canada. Version Number 1, Issue: November 24, 2010.
- Hashimura H, Ueda C, Kawabata J, Kasai T. 2001. Acetyl-CoA carboxylase inhibitors from avocado (*Persea americana* Mill.) fruits. Biosci Biotechnol Biochem. 65:1656-1658.
- Jensen, Lloyd B. 1951. Process for extraction of antibiotic material. US 2,550,254. SWIFT & CO. United States.
- Kabuki, T., Nakajima, H., Arai, M., Ueda, S., Kuwabara, Y., Dosako, S. 2000. Characterization of novel antimicrobial compounds from mango (*Mangifera indica* L.) kernel seeds. Food Chem. 71:61-66.
- Kashman, Y., Néeman, I. and Lifshitz, A. 1969. New Compounds from Avocado Pear. Tetrahedron. 25:4617-4631.
- Kim, O.K., Murakami, A., Nakamura, Y., Takeda, N., Yoshizumi, H., Ohigashi, H. 2000a. Novel nitric oxide and superoxide generation inhibitors, persenone A and B, from avocado fruit. Journal of Agricultural and Food Chemistry 48 (5), pp. 1557-1563.
- Kim, O.K., Murakami, A., Nakamura, Y., Kim, H.W., Ohigashi, H. 2000b. Inhibition by (-)-Persenone A-related Compounds of Nitric Oxide and Superoxide Generation from Inflammatory Leukocytes. Bioscience, Biotechnology and Biochemistry 64 (11), pp. 2500-2503.

Kim, O.K., Murakami, A., Takahashi, D., Nakamura, Y., Torikai, K., Kim, H.W., Ohigashi, H. 2000c. An Avocado Constituent, Persenone A, Suppresses Expression of Inducible Forms of Nitric Oxide Synthase and Cyclooxygenase in Macrophages, and Hydrogen Peroxide Generation in Mouse Skin. *Bioscience, Biotechnology and Biochemistry* 64 (11), pp. 2504-2507.

King, W., Ming, X. Antibacterial composition for control of gram positive bacteria in food applications. US 6,620,446B2. Sep 16, 2003.

Kobiler, I., Prusky, D., Midland, S., Sims, J.J., Keen, N.T. 1993. Compartmentation of antifungal compounds in oil cells of avocado fruit mesocarp and its effect on susceptibility to *Colletotrichum gloeosporioides*. *Physiol. Mol. Plant Pathol.* 43: 319-328.

Maseko, R.B. 2006. Synthesis of authentic organic standards of antibacterial compounds isolated from avocados. Master of Science Thesis. Tshwane University of Technology, South Africa.

MacLeod, J.K. and Schaeffler, L. A Short Enantioselective Synthesis of a Biologically Active Compound from *Persea Americana*. *J. Nat. Prod.*, vol. 58., no. 8, pp. 1270-1273 (August 1995).

Monticello, D.J. Control of microbial growth with lantibiotic/lysozyme formulations. US 5,458,876. Oct 17, 1995.

Murakoshi, S., Isogai, A., Chang, C.F., Kamikado, T., Sakurai, A., Tamura, S. The effects of two components from avocado leaves (*Persea americana* Mill.) and related compounds on the growth of silkworm larvae. *Bombyx mori* L. *Nippon Oyo Dobutsu Konchu Gakkaishi* 1976;20:87-91.

NCCLS M100-S12: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement (ISN 1-56238-454-6).

Néeman, I., Lifshitz, A., Kashman, Y. 1970. New antibacterial agent isolated from the avocado pear. *Applied microbiology*, 470-473.

Oberlies, N.H., Rogers, L.L., Martin, J.M. and McLaughlin, J.L. 1998. Cytotoxic and Insecticidal Constituents of the Unripe Fruit of *Persea americana*. *J. Nat. Prod.* 61:781-785.

Oelrichs, P.B., Ng, J.C., Seawright, A.A., Ward, A., Schaffeler, L., MacLeod, J.K. 1995. Isolation and identification of a compound from avocado (*Persea americana*) leaves which causes necrosis of the acinar epithelium of the lactating mammary gland and the myocardium. *Natural Toxins*, 3(5):344-349

Perumalla, A.V.S., Hettiarachchy, N.S. 2011. Green tea and grape seed extracts - Potential applications in food safety and quality. *Food Research International*. 44(4): 827-839.

Prusky, D., Keen, N.T., Sims, J.J., Midland, S.L., 1982. Possible involvement of an antifungal diene in the latency of *Colletotrichum gloeosporioides* on unripe avocado fruits. *Phytopathol.* 72 (12), 1578.

Prusky, D., Plumbley, R.A., Koliber, I., 1991a. Modulation of natural resistance of avocado fruits to *Colletotrichum gloeosporioides* by CO₂. *Plant Pathol.* 40, 45.

Prusky, D., Koliber, I., Fishman, Y., Sims, J.J., Midland, S.L., Keen, N.T., 1991b. Identification of an Antifungal Compound in Unripe Avocado Fruits and its Possible Involvement in the Quiescent Infections of *Colletotrichum gloeosporioides*. J. Phytopathol. 132, 319.

Ramos-Jerz, M.D. Phytochemical analysis of avocado seeds (*Persea americana* Mill., c.v. Hass). [Ph. D. Dissertation], Göttingen, Alemania, 2007. Technischen Universität Braunschweig.

Rayman, M.K. 1981. Nisin: a possible alternative or adjunct to nitrite in the preservation of meats. Applied and Environmental Microbiology. 41(2):375-380.

Rodríguez-Carpena, J.G., Morcuende, D., Andrade, M.J., Kylli, P. and Estévez, M. 2011. Avocado (*Persea americana* Mill.) phenolics, in vitro antioxidant and antimicrobial activities and inhibition of lipid and protein oxidation in porcine patties. J. Agric. Food Chem. 59:5625-5635.

Rodriguez-Saona, C., Millar, J.G., Trumble, J.T. 1997. Growth inhibitory, insecticidal, and feeding deterrent effects of (12Z,15Z)-1-acetoxy-2-hydroxy-4-oxo-heneicosa-12,15-diene, a compound from avocado fruit, to *Spodoptera exigua*. Journal of Chemical Ecology, 23(7):1819-1831

Seawright A.A., Oelrichs P.B., Ng, J.C., MacLeod J.K., Ward, A., Schaffeler, L., Carman, R.M. 1995. Method of treatment of cancer as well as method of inhibition of lactation in mammals. Patent Coop. Treaty Int. Appl. No WO 95/22969, Astralian National University, Australia.

Sivanathan, S., Adikaram, N.K.B., 1989. Biological Activity of Four Antifungal Compounds in Immature Avocado. Journal of Phytopathology, 125(2): 97 - 109

Smola, M. 2007. Contribution à l'étude de la formulation et de l'analyse physicochimique de formulations pédiatriques microémulsionnées. [Docteur in Sciences Pharmaceutiques]. Universite Louis Pasteur Strasbourg. France.

Sugiyama, T., Sato, A. and Yamashita, K. Synthesis of all four stereoisomers of antibacterial component of avocado. Agric. Biol. Chem., 46(2), 481-485 (1982).

Tang, Y., Shi, Y., Zhao, W., Hao, G. and Le, G. 2008. Inhibition of Food-Borne Pathogens by T1, a Novel Antimicrobial Peptide as a Potential Food Preservative. International Journal of Food Engineering. Vol 4, Iss. 4, Art, 14. p. 1-19.

Ugbogu, O.C. & Akukwe, A.R. 2009. The antimicrobial effect of oils from *Pentaclethra macrophylla* Bent, *Chrysophyllum albidum* G. Don and *Persea gratissima* Gaerth F on some local clinical bacteria isolates. African Journal of Biotechnology, 8(2): 285-287.

Pollack S, Perez A, Plattner K. 2010. Fruit and tree nuts outlook. Economic Research Service. United States Department of Agriculture USDAFTS-341/March 26, 2010.

Valeri, A., and N. Gimeno. 1954. Phytochemical and toxicological study of pericarp of the avocado pear. Rev. Med. Vet. Parasitol (Maracay) 13:37.

Wilhoit, D. Film and method for surface treatment of foodstuffs with antimicrobial compositions. US 5,573,797. Nov 12, 1996.

Wilhoit, D. Antimicrobial composition for surface treatment of foodstuffs. US 5,573,800. Nov 12, 1996.


Wilhoit, D. Surface treatment of foodstuffs with antimicrobial compositions. US 5,573,801. Nov 12, 1996.

Yang, H., Li, X., Tang, Y., Zhang, N., Chen, J. and Cai, B. 2009. Supercritical fluid CO₂ extraction and simultaneous determination of eight annonaceous acetogenins in Annona genus plant seeds by HPLC-DAD method. J Pharm Biomed Anal. 49:140-144.

Claims:

1. A method of inhibiting bacterial spore germination on or in a product, said method comprising:

providing an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,

A is selected from the group consisting of O and OH,


n is 0 or 1, and

m is 0 or 1;

and

applying the inhibitor compound on or in the product to inhibit bacterial spore germination on or in the product.

2. The method of claim 1, wherein the inhibitor compound has the formula:



wherein:


R is selected from the group consisting of H and C₁₋₆ alkyl;

A is selected from the group consisting of O and OH;

n is 0 or 1; and

m is 0 or 1.

3. The method of claim 1, wherein the inhibitor compound has the formula:



wherein:


R is selected from the group consisting of H and C₁₋₆ alkyl;

A is selected from the group consisting of O and OH;


n is 0 or 1; and

m is 0 or 1.

4. The method of claim 1, wherein the inhibitor compound has the formula:



5. The method of claim 1, wherein the inhibitor compound has the formula:



6. The method of claim 1, wherein the method is carried out to inhibit germination of bacterial spores selected from the group consisting of *Clostridium*, *Bacillus*, *Alicyclobacillus*, and combinations thereof.


7. The method of claim 1, wherein the method is carried out to inhibit germination of bacterial spores selected from the group consisting of *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus subtilis*, *Bacillus licheniformis*, *Alicyclobacillus acidoterrestris*, *Alicyclobacillus acidophilus*, and combinations thereof.

8. The method of claim 1, wherein the method is carried out to inhibit germination of heat shocked bacterial spores.
9. The method of claim 1, wherein the product is a food product.
10. The method of claim 9, wherein the food product is selected from the group consisting of fish, crustaceans, fish substitutes, crustacean substitutes, meat, meat substitutes, poultry products, vegetables, greens, sauces, emulsions, beverages, juices, wines, beers, dairy products, egg-based products, jams, jellies, grain-based products, baked goods, confectionary products, and combinations thereof.
11. The method of claim 9 or 10, wherein the food product is a ready to eat food product stored under refrigerated conditions.
12. The method of claim 1, wherein the product is a personal care product.
13. The method of claim 12, wherein the personal care product is selected from the group consisting of creams, gels, powders, lotions, sunscreens, lipstick, body wash, herbal extracts, formulations that support the growth of bacteria, and combinations thereof.
14. The method of claim 1, wherein the product is a surface to be treated.
15. The method of claim 14, wherein the surface to be treated is selected from the group consisting of counter tops, doors, windows, handles, surgical equipment, medical tools, contact surfaces that can contaminate humans or animals, and combinations thereof.
16. The method of claim 1, wherein the inhibitor compound is applied as a component of a composition, said composition further comprising:
a carrier.
17. The method of claim 16, wherein the composition further comprises:

an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

18. The method of claim 16, wherein the inhibitor compound in the composition is applied at a concentration of at least about 7.8 $\mu\text{g/ml}$.

19. Use of an inhibitor compound of the formula



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,


A is selected from the group consisting of O and OH,

n is 0 or 1, and

m is 0 or 1;

for the inhibition of a germination of a bacterial spore in a subject.

20. Use of an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl,

A is selected from the group consisting of O and OH,

n is 0 or 1; and

m is 0 or 1;

in the manufacture of a medicament for the inhibition of germination of a bacterial spore in a subject.

22. The use of the inhibitor compound of claim 19 or 20 wherein:
the subject is susceptible to having bacterial spores.


CC(=O)OC[C@H](O)C(=A)/C=C/C(C)(C)CCCC(C)[C@@H]1CC[C@H](C)[C@H]1C/C=C/C=C\R

R is selected from the group consisting of H and C₁₋₆ alkyl;
A is selected from the group consisting of O and OH;
n is 0 or 1; and
m is 0 or 1.


CC(=O)OCC(O)C(=A)/C=C/C(C)(C)CCCC(C)(C)[CH2]n[CH2]m/C=C/C=C\R

R is selected from the group consisting of H and C₁₋₆ alkyl;
A is selected from the group consisting of O and OH;
n is 0 or 1; and
m is 0 or 1.

CA 2807779 2018-03-29



26. The use of the inhibitor compound of claim 19 or 20, wherein the inhibitor compound has the formula:




27. The use of the inhibitor compound of claim 19 or 20, wherein the bacterial spore is selected from the group consisting of *Clostridium*, *Bacillus*, *Alicyclobacillus*, and combinations thereof.

28. The use of the inhibitor compound of claim 19 or 20, wherein the bacterial spore is selected from the group consisting of *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus subtilis*, *Bacillus licheniformis*, *Alicyclobacillus acidoterrestris*, *Alicyclobacillus acidophilus*, and combinations thereof.

29. The use of the inhibitor compound of claim 19 or 20, wherein the inhibitor compound is in an oral dosage form, a dermal dosage form, a parenteral dosage form, a nasal dosage form, an ophthalmic dosage form, an optical dosage form, a sub-lingual dosage form, a rectal dosage form, a gastric dosage form, a vaginal dosage form, or combinations of dosage forms thereof.


30. A composition comprising an inhibitor compound of the formula:



wherein: R is selected from the group consisting of H and C₁₋₆ alkyl, A is selected from the group consisting of O and OH, n is 0 or 1, and m is 0 or 1, in a suitable carrier for use in the inhibition of a germination of a bacterial spore in a subject.

31. The composition of claim 30, wherein the subject has bacterial spores or is susceptible to having bacterial spores.

32. The composition of claim 30, wherein the inhibitor compound is selected from the group consisting of:



33. The composition of claim 30, wherein the bacterial spore is selected from the group consisting of *Clostridium*, *Bacillus*, *Alicyclobacillus*, and combinations thereof.

34. The composition of claim 30, wherein the bacterial spore is selected from the group consisting of *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus subtilis*, *Bacillus licheniformis*, *Alicyclobacillus acidoterrestris*, *Alicyclobacillus acidophilus*, and combinations thereof.


35. The composition of claim 30, wherein the composition is in an oral dosage form, a dermal dosage form, parenteral dosage form, a nasal dosage form, an ophthalmic dosage

form, an optical dosage form, a sub-lingual dosage form, a rectal dosage form, a gastric dosage form, a vaginal dosage form, or combinations of dosage forms thereof.

36. The composition of claim 30, wherein the composition further comprises an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

37. The composition of claim 30, wherein the inhibitor compound in the composition is present at a concentration of at least about 7.8 µg/ml.

38. A compound of the formula:



wherein:


R is selected from the group consisting of H and C₁₋₆ alkyl;

A is O;


n is 0 or 1; and

m is 0 or 1.

39. The compound of claim 38, wherein the compound has the formula:



40. The compound of claim 38, wherein the compound has the formula:



41. A pharmaceutical composition comprising:
the compound of claim 38, and
a pharmaceutically acceptable carrier.

42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is for use in inhibiting germination of a bacterial spore and the compound is present in a concentration of at least about 7.8 $\mu\text{g/ml}$.

43. The pharmaceutical composition of claim 41 further comprising:
an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

44. A food product composition comprising:
a food product and
the compound of claim 38.

45. The food product composition of claim 44, wherein the compound is present in a concentration of at least about 7.8 $\mu\text{g/ml}$.

46. The food product composition of claim 44, wherein the food product is selected from the group consisting of fish, crustaceans, fish substitutes, crustacean substitutes, meat, meat substitutes, poultry products, vegetables, greens, sauces, emulsions, beverages, juices, wines, beers, dairy products, egg-based products, jams, jellies, grain-based products, baked goods, confectionary products, and combinations thereof.

47. The food product composition of any one of claims 44 to 46, wherein the food product is a ready to eat food product stored under refrigerated conditions.

48. The food product composition of claim 44 further comprising:
an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

49. A personal care product composition comprising:
a personal care product and
the compound of claim 38.

50. The personal care product composition of claim 49, wherein the compound is present in a concentration of at least about 7.8 µg/ml.

51. The personal care product composition of claim 49, wherein the personal care product is selected from the group consisting of creams, gels, powders, lotions, sunscreens, lipstick, body wash, herbal extracts, formulations that support the growth of bacteria, and combinations thereof.

52. The personal care product composition of claim 49 further comprising:
an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.


53. A cleaning product composition comprising:
a cleaning product and
the compound of claim 38.

54. The cleaning product composition of claim 53, wherein the compound is present in a concentration of at least about 7.8 µg/ml.

55. The cleaning product composition of claim 53 further comprising:
 an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

56. A method of providing an antimicrobial or antibacterial effect on or in a product, said method comprising:

providing an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;

A is O;


n is 0 or 1; and

m is 0 or 1.


and

applying the inhibitor compound on or in the product to provide an antimicrobial or antibacterial effect on or in the product.

57. The method of claim 56, wherein the inhibitor compound has the formula:



58. The method of claim 56, wherein the inhibitor compound has the formula:



59. The method of claim 56, wherein the method is carried out to provide an antimicrobial or antibacterial effect against microbes selected from the group consisting of *Clostridium*, *Listeria*, *Bacillus*, and combinations thereof.

60. The method of claim 56, wherein the method is carried out to provide an antimicrobial or antibacterial effect against microbes selected from the group consisting of *Clostridium sporogenes*, *Listeria monocytogenes*, *Bacillus subtilis*, and combinations thereof.

61. The method of claim 56, wherein the product is a food product.

62. The method of claim 61, wherein the food product is selected from the group consisting of fish, crustaceans, fish substitutes, crustacean substitutes, meat, meat substitutes, poultry products, vegetables, greens, sauces, emulsions, beverages, juices, wines, beers, dairy products, egg-based products, jams, jellies, grain-based products, baked goods, confectionary products, and combinations thereof.

63. The method of claim 61 or 62, wherein the food product is a ready to eat food product stored under refrigerated conditions.

64. The method of claim 56, wherein the product is a personal care product.

65. The method of claim 64, wherein the personal care product is selected from the group consisting of creams, gels, powders, lotions, sunscreens, lipstick, body wash, herbal extracts, formulations that support the growth of bacteria, and combinations thereof.

66. The method of claim 56, wherein the product is a surface to be treated.


67. The method of claim 66, wherein the surface to be treated is selected from the group consisting of counter tops, doors, windows, handles, surgical equipment, medical tools, contact surfaces that can contaminate humans or animals, and combinations thereof.

68. The method of claim 56, wherein the inhibitor compound is applied as a component of a composition, said composition further comprising:
a carrier.

69. The method of claim 68, wherein the composition further comprises:
an antimicrobial substance selected from the group consisting of nitrite compounds, nisin, bacteriocins, ethyl lauroyl arginate, ethylene diaminetetraacetic acid compounds, ascorbic acid compounds, benzoic acid compounds, and combinations thereof.

70. The method of claim 68, wherein the inhibitor compound in the composition is applied at a concentration of at least about 7.8 µg/ml.

71. Use of an inhibitor compound of the formula:



wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;

A is O;

n is 0 or 1; and


m is 0 or 1.

in the manufacture of a medicament for providing an antimicrobial or antibacterial effect in a subject.


72. The use of the inhibitor compound of claim 71 wherein:
the subject has a microbe.

73. The use of the inhibitor compound of claim 71 wherein:
the subject is susceptible to having a microbe.

74. The use of the inhibitor compound of claim 71, wherein the inhibitor
compound has the formula:



75. The use of the inhibitor compound of claim 71, wherein the inhibitor
compound has the formula:



76. The use of the inhibitor compound of claim 71, wherein the microbe is
selected from the group consisting of *Clostridium*, *Listeria*, *Bacillus*, and combinations thereof.

77. The use of the inhibitor compound of claim 71, wherein the microbe is
selected from the group consisting of *Clostridium sporogenes*, *Listeria monocytogenes*, *Bacillus subtilis*, and combinations thereof.

78. The use of the inhibitor compound of claim 71, wherein the inhibitor
compound is in an oral dosage form, a dermal dosage form, a parenteral dosage form, a nasal
dosage form, an ophthalmic dosage form, an optical dosage form, a sub-lingual dosage form, a
rectal dosage form, a gastric dosage form, a vaginal dosage form, or combinations of dosage
forms thereof.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6



A**B**

Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18